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ABSTRACT
DOMAIN-FOCUSED CRISPR SCREEN IDENTIFIES HRI AS A REGULATOR OF
FETAL HEMOGLOBIN IN HUMAN ERYTHROID CELLS
Jeremy D. Grevet
Gerd A. Blobel

Increasing fetal hemoglobin (HbF) levels in adult red blood cells provides clinical benefit
to patients with sickle cell disease and some forms of β-thalassemia. To identify potentially
druggable HbF regulators in adult human erythroid cells, we employed a protein kinasedomain focused CRISPR/Cas9-based genetic screen with a newly optimized sgRNA
scaffold. The screen uncovered the heme-regulated inhibitor HRI (also known as
EIF2AK1), an erythroid-specific kinase that controls protein translation, as an HbF
repressor. HRI depletion markedly increased HbF production in a specific manner and
reduced sickling in cultured erythroid cells. Diminished expression of the HbF repressor
BCL11A accounted in large part for the effects of HRI depletion. Taken together, these
results suggest HRI as a potential therapeutic target for hemoglobinopathies.
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CHAPTER 1: INTRODUCTION
In 1949, Linus Pauling published on the discovery of sickle cell anemia as the first
molecular disease (1, 2). He first heard about the disease from hematologist William Castle
who told him about patients of his whose red blood cells sickled in venous circulation but
not in arterial blood (2). Pauling postulated that if the disease’s manifestation was
determined by oxygen levels, it may reflect a molecular defect in hemoglobin. In this paper,
Pauling and his group showed that hemoglobin from normal patients had a different
electrophoretic mobility than hemoglobin from sickle patients (1). The cause for this
difference though was unknown. In 1956, Vernon Ingram, working along with Francis
Crick at the Cavendish Laboratories, showed by protein fingerprinting (essentially twodimensional chromatography) that the amino acid composition of sickle hemoglobin
differed from its normal counterpart (3). This not only pinpointed the molecular etiology
of sickle cell disease, but it was also a major contribution to Crick’s formulation of the
Central Dogma in showing that inherited genetic mutations can lead to altered protein
products (3).
The pathophysiology of sickle cell disease has been well established for decades now.
It is the classic example of a Mendelian disorder. Since Pauling’s paper, researchers have
made great strides towards developing improved treatment modalities for this disease,
some of which are excitingly reaching patients. But sickle cell disease still remains a
remarkably challenging disease to manage clinically, as SCD patients continue to face
severe pain crises, and complications that affect nearly every organ. There is also much
that remains to be learned about more basic aspects of erythroid cells. How red blood cells
develop, how their gene expression profiles are regulated, and how these may be
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manipulated for therapeutic purposes are all still open questions. Seventy years after
Pauling’s publication, erythroid biology continues to be a fascinating area of research.
In this introduction, we will overview how erythroid cells are produced during the
course of development, how they differentiate from progenitor cells to form fully mature
red blood cells that can carry out oxygen transport, and the gene regulation programs that
underlie these processes. We will focus on the regulation of the globin genes as a key
process of erythropoiesis. This will bring us to the concept of hemoglobin switching,
whereby globin expression transitions from fetal to adult type genes shortly after birth. We
will discuss the clinical implications of globin switching in the context of
hemoglobinopathies. This will then lead us to a discussion of the molecular regulators of
hemoglobin switching, and how this knowledge is being used for the development of new
therapeutic strategies for diseases such as thalassemias and sickle cell anemia.

1.1 Erythropoiesis and globin switching

1.1.1 Ontogeny of erythropoiesis
During the course of development, the site of production of red blood cells
transitions between different organs. It begins in the yolk sac, then takes place in the ventral
aortic wall, subsequently the fetal liver, and finally in the bone marrow. This is a complex
process that is only briefly summarized here. Erythroid cells are first produced in the yolk
sac of the developing embryo in cellular structures termed blood islands (4, 5). These
groups of cells contain both erythroid and endothelial cells and arise from a common
precursor with bilineage potential termed the hemangioblast (4). Red blood cells produced
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from the yolk sac are released in the circulation as precursors and undergo differentiation
in the periphery (4, 5). Thus, in these early stages of development, circulating red cells are
a heterogeneous population of undifferentiated, mitotic, and nucleated erythroid
precursors, and mature, enucleated red blood cells (5). These first stages of red blood cell
production are collectively termed primitive erythropoiesis.
Definitive erythroid cells are in contrast smaller in size, anucleate and mitotically
inactive, and are produced from early stages of fetal development throughout adult life (5).
It is thought that these cells arise from two origins (5). The first site of definitive
erythropoiesis is the yolk sac where these cells are thought to arise from common erythromyeloid progenitors or endothelial cells (5). Definitive progenitors produced in the yolk
sac may also contribute to seeding the fetal liver in its earliest stage of development (4).
The second site of origin of definitive erythroid cells is a specific region of the
ventral wall of the aorta termed the aorto-gonadal-mesonephros (AGM) (5, 6). The first
hematopoietic stem cells (HSCs) are thought to be produced in this region (5, 6). HSCs
derived from the AGM have been shown to have the ability to both self-renew and
differentiate into all lineages of the hematopoietic system as evidenced by bone marrow
transplantation assays (6). The close association of HSCs and the ventral aorta suggests
that these cells may be of endothelial origin. This has been shown to have important
implications for cellular reprogramming. Two recent studies have shown it is possible to
directly convert adult endothelial cells to HSCs (7, 8). One of these studies demonstrated
the direct conversion of murine adult endothelium to HSCs culture in vitro by the
transduction of a set of four transcription factors (7). The derived HSCs were shown to be
able to reconstitute all lineages of the hematopoietic system after transplantation into
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lethally irradiated mice. The second study used human iPSCs as a starting material, which
were converted to endothelial cells and then to HSCs by the transduction of seven
transcription factors (8). Similarly, these derived cells were able to produce essentially all
hematopoietic lineages in transplanted mice. RNA-seq showed that the transcriptome of
the converted cells was remarkably similar to bona-fide HSCs, though the correlation was
not perfect (8). Further improvements to these reprogramming protocols will certainly
ameliorate the efficiency of conversion and the similarity of derived cells to their true
counterparts. But these studies show great progress towards the goal of readily producing
patient-derived HSCs for therapeutic purposes, and also highlight the close relationship
between HSCs and the endothelium.
HSCs derived in the AGM migrate to the fetal liver where they support
erythropoiesis and the production of all other hematopoietic lineages until birth (4, 5). In
humans, the fetal liver is the site of hematopoiesis for the second two trimesters of gestation
(4). At birth, fetal liver HSCs migrate to the bone marrow, which is the site of
hematopoiesis for the remainder of life (4).

1.1.2 Definitive erythropoiesis
In adults, red blood cells are the most common cell type of the blood. They have a
life span of 120 days, and must be constantly replenished. Erythroid cells are produced
from HSCs in the bone marrow which also give rise to all lineages of the blood system (4).
Before giving rise to erythroid cells, HSCs differentiate to a common myeloid precursor
(CMP) and subsequently to a megakaryocyte-erythroid progenitor (MEP) (Figure 1.1) (4).
It is important to note that while hematopoiesis has traditionally been conceived of in this
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stepwise fashion, recent studies are suggesting that lineage decisions may occur much
earlier in this tree than previously appreciated (9, 10). Furthermore, these differentiation
processes most likely do not occur in discrete steps but rather over a continuum of cell
states as shown by recent single-cell approaches.
Once committed to the erythroid lineage, MEPs undergo a well-defined process of
differentiation to terminal red blood cells. This process is characterized by specific stages
of maturation that can be described in 3 main levels: erythroid progenitors which comprise
burst forming units (BFU-Es) and colony forming units (CFU-Es), erythroid precursors
which include pro-erythroblast (ProEs), basophilic (Baso), polychromatic (PolyE), and
orthochromatic (OrthoE) erythroblast, and terminal erythroid cells which are reticulocytes
and mature red blood cells (Figure 1.1) (5). Erythroid progenitors are defined by their
ability to grow colonies on methylcellulose (4). BFU-Es are characterized by their rapid
proliferation. CFU-Es have less proliferative capacity but are 5 to 8-fold more abundant in
the bone marrow than BFU-Es and can still undergo up to 5 cellular divisions (5). Erythroid
progenitors require erythropoietin for their growth as well as several other cytokines
including stem cell factor, thrombopoietin, intertleukin 3 (IL-3), IL-11 and FLT3-ligand
(5).
Erythroid precursors (ProE, Baso, PolyE, OrthoE) undergo multiple stages of
differentiation to become terminal erythrocytes and these take place in a specific structure
of the bone marrow termed the erythroblastic island (4). These consist of a central
macrophage with cellular protrusions along which erythroid precursors mature. Erythroid
differentiation is characterized by several morphological changes including a reduction in
cellular and nuclear size, cellular membrane changes, a decrease in total RNA content, and
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an increase in heme and globin protein levels (4). The changes in composition of nucleic
acid and protein levels lead to staining patterns that have classically defined these different
stages. These are also accompanied by changes in expression of cell surface markers. CD71
(Transferrin Receptor 1) is abundant in ProEs and decreases as cells mature. CD235a
(glycophorin A) is lowly expressed in ProEs and becomes more abundant during
differentiation (4).
OrthoEs enucleate in the erythroblastic island to produce reticulocytes through a
complex process that involves the movement of nuclei to the cytoplasmic membrane and
their release from the cell (5). Evicted nuclei are phagocytosed by the central macrophage
(5). Reticulocytes are released in the peripheral circulation and undergo further changes
until become fully mature red blood cells (4). Their volume is reduced by approximately
20% as they degrade ribosomes and mitochondria. Red blood cells thus rely on glycolysis
as an energy source, and this explains why glucose-6-phosphate dehydrogenase deficiency
is a common cause of hemolytic anemia. Maturing erythroid cells also position their
cytoskeleton in close association with their cytoplasmic membrane to adopt their
characteristic biconcave shape (11). This confers an optimal surface area for gas exchange
given the small volume of terminal red blood cells (11). The membrane of terminally
differentiated red blood cells is composed of a meshwork of spectrin filaments and actin
junctions closely associated with lipid rafts (11). Recent super-resolution imaging studies
by STORM microscopy have provided additional evidence for a triangular lattice
organization of these spectrin filaments with actin nodes positioned at regular (~80 nm)
intervals of each other (11). This regular organization of the cytoskeleton, as well as its
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close proximity to the cellular membrane may confer optimal biophysical properties to
erythroid cells that allow them to properly circulate through microcapillaries.

1.1.3 Transcriptional regulation of erythropoiesis
Erythroid cells undergo profound changes as they progress from immature, rapidly
dividing progenitors to terminally differentiated red blood cells mostly composed of
hemoglobin. This differentiation program is orchestrated by a core set of transcription
factors, with the DNA binding protein GATA1 being considered one of the master
regulators of erythropoiesis (6). Its homolog GATA2 is expressed in HSCs and
progressively decreases in levels as cells differentiate to MEPs. GATA1 is reciprocally
induced at this stage in a process termed GATA switching (12). This marks a first
commitment to the erythroid lineage as GATA1 begins to occupy many sites previously
bound by GATA2, and de novo sites as well (12). As a key determinant of erythropoiesis,
GATA1 instructs both the repression of genes that support cellular proliferation and other
hematopoietic lineages, as well as the activation of erythroid specific genes (6). These
include cytoskeletal and membrane proteins, cell cycle regulators, components of the heme
biosynthetic pathway, and globins (12). As such, GATA1 plays roles both in transcriptional
repression and activation.
How GATA1 accomplishes these differing functions is too complex to fully review
here, but suffice it to say it performs these diverse roles in part by associating with different
co-factors (13). In a highly simplified view, GATA1 can be found in two main types of
mutually exclusive complexes, GATA1/TAL1/LMO2 and GATA1/FOG1 complexes (6).
The first of these are found at many genes activated by GATA1, including the globin genes
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(12), which will be discussed in greater detail below. Most of the GATA1/TAL1/LMO2
complexes are found in intergenic or intronic regions, and associate with the selfdimerizing looping factor LDB1 (12, 14). These complexes may thus primarily function
through long-range enhancer-promoter interactions. These sites also tend to be co-occupied
by the transcription factor KLF1, which has been shown to also be required for the
differentiation of red blood cells. FOG1 is a co-factor that directly associates with GATA1
(6). It further recruits transcriptional regulators including the NuRD complex which is
composed of histone deacetylases HDAC1/2, MTA1/2, and the ATP-dependent chromatin
remodelers CHD3/4 (15). These regulators are typically associated with transcriptional
repression, and thus GATA1/FOG1 complexes may be thought of as primarily functioning
to silence gene expression. These complexes though are much more complex, as the NuRD
complex, and thus GATA1/FOG1 complexes, can function both as activators or repressors
in a highly context-dependent fashion (16). How these different roles are determined still
remains to be fully elucidated. Several studies have investigated the global changes in
transcript levels during the course of erythroid differentiation (17, 18). These suggest that
GATA1 functions quite extensively in transcriptional repression, with approximately 5,000
genes repressed and 200 activated during GATA1 induction of erythroid maturation in
murine systems normalized by spike-in controls (18).

1.1.4 Proteome of differentiating erythroid cells
A recent study further investigated the proteome of differentiating erythroid cells
by label free whole cell mass spectrometry (19). Though mass spectrometry is more limited
in its dynamic range than RNA-seq, and further complicated by the high levels of
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hemoglobin present in erythroid cells, the authors were able to quantify up to 6,000 proteins
from individual stages of erythropoiesis (19). These data revealed firstly that global protein
levels decrease during erythroid maturation (19), similarly to the decrease in transcript
levels observed previously. Proteins that decreased in levels involve general cellular
processes such as RNA splicing, protein translation, and metabolic pathways. A subset of
proteins was induced during the course of differentiation and these included globins,
AHSP, and BAND3, among others (19). In particular, when globins and AHSP were
subtracted, the total level of proteins was estimated to decrease by about 75% from BFUEs to OrthoEs (19), further showing the extent to which the proteome of erythroid cells is
remodeled during differentiation.
The decrease in total protein levels may reflect the reduced transcriptional activity
of differentiating erythroid cells. Transcript and protein levels though were not closely
correlated across these different stages in this study (19). This may reflect technical
differences between RNA-seq and mass spectrometry in their sensitivities and accuracies
in measurement. But it does appear that post-transcriptional mechanisms play a role in
remodeling the proteome of differentiating red blood cells. Autophagy has long been
implicated in the clearance of cellular components and proteins as factors of this pathway
are induced during erythropoiesis (20). Two recent studies showed that the ubiquitinconjugating enzyme UBE2O plays important roles in protein clearance during reticulocyte
maturation to terminal erythroid cells (21, 22). Deleting this enzyme prevents removal of
many proteins including ribosomal subunits. Finally, translation may also be an important
level at which genes are regulated during erythroid differentiation. A recent study showed
that a number of transcripts in differentiating murine erythroid cells are subject to
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translational control, with a subset of these potentially being regulated by upstream openreading frames in their 5’UTRs (23).

1.1.5 Heme and globin production
The production of heme and globin proteins is one of the most important aspects of
red blood cell maturation as these cells’ primary raison d’être is to transport oxygen in the
circulation. Heme is produced in a clearly defined metabolic process involving 7 enzymatic
reactions taking place either in the cytoplasm or mitochondria, which converts 8 molecules
of glycine and 8 molecules of succinyl CoA to the tetrapyrrole structure of heme (24). The
first of these steps is mediated by 𝛿-aminolevulinate synthase 2 (ALAS2) located in the
mitochondrial matrix which condenses glycine and succinyl CoA to form ALA and CO2
(24). This is the rate limiting step of this metabolic pathway and thus a major regulatory
point for heme production (24). In particular, ALAS2 expression is tightly controlled by
available iron levels (25). This may be intuitive as iron is a key substrate for oxygen binding
by heme, but the mechanism by which this regulation occurs is particularly interesting and
a core feature of cellular iron metabolism regulation. The 5’ UTR of the ALAS2 transcript
contains a hairpin loop motif termed an iron-responsive element (IRE) (25). This element
is bound by an iron-responsive protein (IRP) in low iron conditions and blocks translation
of the downstream ALAS2 open reading frame. In iron replete conditions, IRPs bind iron
which prevents their association with the IRE (25). It is also thought that high iron levels
activate an E3 ligase which ubiquinates IRPs to direct them for proteasomal degradation.
Thus, increased levels of iron stimulate ALAS2 synthesis, which in turn begins heme
production (26).
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Iron is transported into erythroid cells relatively early during maturation as the
transferrin receptor (CD71) is expressed in ProEs. Thus heme synthesis is activated during
this earliest stage of erythropoiesis by the import of iron (26). Shortly thereafter, globins
begin to be expressed. This is in part assisted by heme which inhibits the transcriptional
repressor BACH1 that occupies the globin genes (27), and also by inhibition of the hemeregulated inhibitor (HRI) which leads to translation of globin transcripts (described further
below).
The balanced production of heme and globins presents a notable challenge to
erythroid cells as the presence of either of these in excess can lead to oxidative stress and
be toxic to cells (24). As stated above, heme production begins at early stages of erythroid
maturation, and before globins are synthesized (Figure 1.2) (26). This presents a short time
window during which heme is in excess to globins (26) . Erythroid cells have multiple
systems in place for overcoming this. The first is the feline leukemia virus subgroup C
receptor (FLVCR), a membrane transport protein, which exports heme and is expressed
early in maturation (24). CFU-Es and Pro-Es critically rely on the FLVCR as depleted it is
notably toxic to these cells and prevents proper differentiation, further supporting the
concept that heme is in excess at these early stages (26). The second system in place for
balancing heme and globin levels is the translation initiation regulator heme-regulated
inhibitor (HRI) (28). HRI is a kinase that phosphorylates the translation initiation factor
eIF2⍺ which blocks its proper function in initiating translation globally (28). HRI is
inhibited by heme which in turn favors translation (28). Thus, as heme levels progressively
increase in cells, HRI inhibition stimulates protein translation to favor balanced levels of
heme and globin proteins. Of note, several erythroid diseases including Diamond-Blackfan
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anemia (DBA) and a specific form of myelodysplastic syndrome (MDS) termed 5q minus
syndrome have been linked to genetic defects in the translation machinery, and in particular
ribosomal proteins (26, 29). It is thought that the pathology underlying these diseases may
in part be due to reduced translation of globin proteins, and excess heme leading to
ineffective erythropoiesis (26, 29). These disorders thus further highlight the importance
of balanced production of these two key components of red blood cells.

1.1.6 Hemoglobin switching
Definitive erythroid cells of the fetal liver and the adult bone marrow show a great
degree of overlap in their transcriptomes and chromatin signatures (30). However, there
are a number of important differences between these two different stages of erythroid
ontogeny. This is most notably exemplified by the expression of the globin genes (31). As
presented above, the production of globins is a key process of erythroid differentiation.
Hemoglobin A is a tetramer of 2 α-chains and 2 β-type globin chains (α2β2). The β-type
globin genes are encoded on chromosome 11 and there are multiple forms of these genes:
embryonic globin (ε-globin, HBE), two fetal globin genes (g-globin, HBG1/2), and two
adult globin genes (𝛿- and β-globin, HBD and HBB), with β-globin being the major form
that is expressed during adulthood (Figure 1.4) (31). In primitive erythroid cells, embryonic
globins are primarily expressed. Fetal type globins are the major forms expressed in
definitive erythroid cells of the fetal liver. It is thought that fetal hemoglobin has a stronger
affinity for oxygen that adult hemoglobin which may facilitate oxygen extraction to the
fetal circulation in the placenta. Shortly after birth, fetal globin expression decreases as
adult globins increase in levels in a process commonly referred to as hemoglobin switching
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(31). It is important to note that fetal globin genes specifically evolved in non-human
primates, and thus are not found in lower mammals including mice, which instead have
two embryonic type globin genes.
The locus control region (LCR) is a powerful regulatory element that lies upstream of
β-globin locus, and long-range interactions between the LCR and globin promoters have
been implicated as playing a key role in globin regulation (31). During erythroid
differentiation, GATA1/TAL1/LMO2 complexes binds globin promoters to activate their
transcription (12, 32). Chromosomal conformation capture (3C) assays showed that
GATA1 occupancy at the globin promoters is accompanied by a significant increase in
long-range contacts between the LCR and globin promoters as these genes are activated
(32). The interactions between the LCR and globin promoters were further shown to
causally underlie the transcriptional activation of these genes. Tethering the looping factor
LDB1, which normally associates with GATA1/TAL1/LMO2 complexes, to the β-globin
promoter by the use of artificial zinc-fingers was shown to be sufficient both to induce
long-range interactions between the LCR and the β-globin promoter, and to activate
transcription (33). Tethering LDB1 to fetal globin promoters can reactivate the expression
of these genes in adult erythroid cells, and is further accompanied by the formation of longrange contacts with the LCR (34). The LCR thus plays a critical role in the regulation of
globin genes during development.
In most individuals, fetal hemoglobin is strongly silenced as most adult express
approximately 0.5% HbF as a percentage of total β-type globins. The extent to which this
switch occurs though can vary considerably, and this has important clinical implications,
as high levels of fetal globin are beneficial to patients with genetic disorders of the adult
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β-globin genes (31). This has provided great motivation for understanding this basic
process of gene regulation, and how it may be manipulated, over the past decades (31).

1.3 Hemoglobinopathies
Mutations in the adult globin genes underlie a group of disorders collectively termed
hemoglobinopathies. This group of disorders encompasses some of the most common
genetic disorders worldwide and typically manifest themselves after birth when adult
globins are expressed. There are two main types of hemoglobinopathies affecting the βtype globin genes: β-thalassemia and Sickle Cell Disease (SCD).

1.1.1 β-Thalassemia
Thalassemias arise from mutations resulting in quantitative imbalances of ⍺- to βglobin expression. A wide range of mutations lead to these disorders, with up to 120 ⍺thalassemia mutations (35) and over 250 β-thalassemia mutations described (36).
β-thalassemia is typically caused by point mutations rather than deletions. These
mutations can affect any regulatory point of β-globin expression, leading to decreased
production of β-globin (36). The extent to which beta-globin is reduced determines the
severity of the disorder. Mutations that lead to a complete loss of β-globin expression are
termed β0-thalassemia. Such mutations typically affect β-globin splicing, transcript
stability, or translation (mutated initiation codon, nonsense or frameshift mutations). These
can also involve deletions of the β-globin genes, though these types of mutations are found
less commonly (36). β+ and β ++ thalassemia refer to mutations that only partially reduce
β -globin expression. These can involve the beta-globin polyadenylation signal (β+), β-
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globin promoter (β++), or the 5’UTR (β++) (36). Though less common, some deletions
involve the β-globin gene or the locus control region and result in β0-thalassemia.
While the specific genetic etiologies of thalassemias are diverse, all result in an excess
of free-globin chains which are toxic. The downstream pathological effects of these excess
⍺-globin chains are quite complex (36). Free ⍺-globin chains auto-oxidize, leading to the
formation of reactive oxygen species (ROS) (36). This in turn leads to oxidation of
membranes proteins which causes hemolysis, and activation of apoptotic pathways
resulting in ineffective erythropoiesis.

1.2.2 Sickle Cell Disease
Sickle Cell Disease (SCD) is one of the most common genetic disorders worldwide.
It is caused by a point mutation in the β-globin gene (Glu6Val, rs334) and is inherited as
an autosomal recessive Mendelian trait (37). Heterozygotes are typically unaffected, but
homozygous patients suffer from both acute and chronic complications. In deoxygenated
conditions, this mutation leads to polymerization of hemoglobin, causing sickling of red
blood cells. Vaso-occlusion due to altered red blood cell shape and hemolysis constitute
the basis for the pathophysiology of this disease. Endothelial inflammation and aberrant
expression of adhesion protein on sickle red blood cells further promote vaso-occlusive
events (37). As a result, nearly every organ can be affected by SCD and the complications
are thus numerous. These include acute chest syndrome, stroke, right heart failure,
hyposplenism, increased risk of infection, renal failure, priapism, and retinopathy (37).
Furthermore, acute red blood cell sickling leads to ischemic events that cause severe pain
crises, which are one of the most difficult complications to manage for patients with SCD.
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While treatment modalities such as the anti-sickling agent hydroxyurea are available, the
median life expectancy for SCD patients is still of less than 40 years of age (37).
An estimated 100,000 patients with SCD live in the United States, and
approximately 2 to 3 million people live with the disease worldwide (37). The prevalence
is highest in sub-Saharan Africa, South America, the Middle East, and India. The regions
in which SCD is most prevalent are endemic for malaria as sickle cell trait is known to
have protective effects against Plasmodium parasites, which carry out part of their life
cycle in erythroid cells (37). The exact mechanism of protection though is still unknown.
The sickle mutation has thus been maintained in the population by the selective pressure
of malaria and is thus a classic example of a balanced polymorphism (37). Several
haplotypes of the sickle mutation, defined by specific restriction sites in the globin locus,
have been identified in various geographical locations (37). These include the Bantu,
Benin, Cameroon, Senegal, and Arab-Indian haplotypes, and suggested the sickle cell
mutation had originated independently in these disparate geographical locations. A recent
study that fine mapped variants surrounding the sickle variant using 1000 Genomes Project
whole-genome sequencing data put the multi-center hypothesis into question (38). This
study found that the sickle mutation in these different haplotypes is in stronger linkage
disequilibrium with variants that are more closely located to it than the previously
described haplotypes (38). This suggests that the sickle mutation may thus have arisen in
sub-Saharan Africa in a single population when malaria was already present, and was
subsequently disseminated throughout the African continent and the world by migration
and slave routes. Future work will further clarify whether this truly reflects the evolutionary
history of this mutation.
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SCD prevalence is projected to increase over the next decades (39, 40). In
developed countries, this is largely due to the improvements in care for SCD patients which
include newborn screening, antibiotic prophylaxis, stroke prevention, hydroxyurea
treatment, and allogeneic bone-marrow transplantation which still remains the only
curative option for patients with SCD (39, 40). The median survival for SCD patients in
high-income countries is now of more than 60 years of age (37). In developing countries,
approximately 90% of SCD deaths occur in the first 5 years of life due to a lack of access
to care and in particular antibiotic prophylaxis (37). Improvements in basic aspects of
healthcare in these countries will certainly lead to an increase in the number of people
living with SCD in these countries. Genetic testing may offer opportunities to curb the
increased prevalence of SCD, but having the proper resources to put these types of
programs in place, and especially in developing countries where cultural differences can
go against such efforts, it is still difficult to envisage such strategies being truly effective.
While SCD is caused in all patients by the same point mutation in the β-globin
gene, its severity varies considerably between individuals (37). A number of environmental
factors have been implicated as modifiers of the disease. High temperatures, high humidity,
low air quality, smoking, and high altitude have all been suggested to favor red cell
sickling, though the specific mechanisms underlying these effects remain to be fully
elucidated (37). Genetic modifiers of SCD have been characterized in far greater detail.
One of these is ⍺-thalassemia, in which one or more copies of the ⍺-globin genes are
defective or deleted (35). ⍺-thalassemia leads to reduced levels of hemoglobin in the cell
and thus less detrimental polymerization, and is co-inherited in up to a third of SCD patients
of African origin and up to half of those in the Mediterranean basin and India (37). The co-
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inheritance of ⍺-thalassemia with SCD is associated with reduced hemolytic events, but
may favor pain crises and vaso-occlusion. Lower levels of ⍺-globin are thought to lead to
reduced tetramerization of sickle hemoglobin and thus reduce its polymerization. A
number of other genetic modifiers have been implicated in SCD, including genes that play
important roles in the development of cerebrovascular disease and stroke, but many of
these associations still remain to be further elucidated (37).

1.3 Genetic modifiers of HbF silencing

1.3.1 GWAS studies
The best characterized genetic modifier of SCD and β-thalassemia is fetal
hemoglobin (HbF). As explained above, fetal hemoglobin is expressed at low levels in
most adults, but there is considerable inherited natural variation in the extent to which this
occurs. Inherited mutations leading to significantly increased levels of HbF are referred to
as Hereditary Persistence of Fetal Hemoglobin (HPFH) (31). In the context of
hemoglobinopathies, HPFH has considerable clinical benefits. Observational studies have
shown that SCD patients with high levels of HbF have fewer complications and
significantly improved survival outcomes (Figure 1.4) (41). Uncovering the genetic
underpinnings of HbF silencing in adult erythroid cells has thus been a major goal in the
field. GWAS studies have been instrumental towards this by identifying genetic variants
associated with high HbF levels (42). Three loci have emerged from these studies, with
variants mapping to the HBS1L-MYB locus, BCL11A, and the β-globin locus itself (Figure
1.5).
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HBS1L-MYB
The variants of the HBS1L-MYB locus associated with high HbF levels map to a
regulatory element in this region that is also associated with a number of other erythroid
traits such as mean corpuscular hemoglobin, mean corpuscular volume, and red blood cell
count (43). Knockdown of MYB has been shown in primary erythroid cultures to induce
HbF, though the mechanism by which it represses the fetal globin genes still remains to be
fully elucidated (31). Targeting MYB for therapeutic purposes may present challenges
though as this factor plays diverse roles in the hematopoietic system, and its depletion may
have adverse effects on erythroid viability and differentiation (43).

BCL11A
BCL11A is a transcription factor that has now been extremely well characterized as a
major repressor of fetal hemoglobin. Initial studies showed that a specific isoform of
BCL11A is expressed in adult erythroid cells (44) (BCL11A XL, which contains a Cterminal zinc-finger required for HbF silencing (45)) and knockdown of BCL11A in these
cultures induces fetal hemoglobin. The effects on fetal hemoglobin were remarkably
specific and did not impair cell viability or erythroid differentiation (44). Further murine
in vivo models showed that Bcl11a knockout also induced mouse embryonic type globins
(46), as well as a correction of red blood cell sickling in a humanized mouse model of SCD
(47). The mechanism by which BCL11A functions to repress the fetal globin genes had
remained elusive until recently. BCL11A had previously been shown to associate with
multiple members of the NuRD complex (48), which are all known transcriptional
repressors. It had remained unclear though whether BCL11A directly recruits these factors
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to the fetal globin promoters, or other regions within the globin locus. This was primarily
due to technical challenges as BCL11A is a notoriously difficult factor on which to perform
traditional chromatin immunoprecipitation. Two recent studies have shown either by
chromatin immunoprecipitation using an ER-tagged BCL11A expressing cDNA cassette
or Cut-&-Run immunoprecipitation that BCL11A occupies multiple regions in the β-globin
locus (45, 49). Notably, these studies showed that BCL11A occupies a specific region (115 cluster) in the proximal promoter of the g-globin genes (Figure 1.6). BCL11A may
thus function by recruiting transcriptional repressors including the NuRD complex to
transcriptionally silence these genes. This was confirmed by mutating the BCL11A binding
sites in these promoters, which abrogated BCL11A occupancy (49), and induced fetal
globin expression (45, 49).
BCL11A is expressed in multiple tissues, including the erythroid lineage, B-cells, and
neurons. In erythroid cells, BCL11A expression is controlled by a regulatory element that
lies in its second intron (50). The GWAS variants originally implicating BCL11A in HbF
repression map to this particular element, which is characterized by active enhancer marks
in adult erythroid cells including H3K27ac and H3K4me1 (50). Chromatin conformation
capture further showed the element forms long-range contacts with the BCL11A promoter
(50). Deleting this element in murine and human erythroid systems leads to a significant
decrease in BCL11A expression, and concomitantly induces HbF levels (50). Saturating
mutagenesis screens of the BCL11A enhancer showed with greater precision that a GATA
element in this enhancer plays a key role in regulating BCL11A expression (51).

20

β-globin locus
A number of HPFH variants map directly to the β-globin locus, some of which lie in
the promoters of the g-globin genes. One of these variants creates a de novo TAL1 binding
site at the -175 site upstream of the g-globin gene promoters (52). Knocking-in this variant
into cells that normally express low HbF levels led to transcriptional activation of these
genes (52). This was accompanied by the recruitment of the looping factor LDB1 and the
formation of long-range contacts with the LCR, further showing the importance of this
regulatory element in controlling globin expression (52). Another recent study showed that
a CCAAT box approximately 100bp upstream of the g-globin TSS plays important roles in
repressing the fetal globin genes (53). Directed mutagenesis of these regions led to a
significant increase in HbF in a human erythroid cell line as well as primary erythroid
cultures (53). Deep sequencing of these edited regions showed a strong enrichment for a
specific 13bp deletion, most likely due to the fact that there is a region of microhomology
within these elements which may favor these precise edits (53). The fact that such precision
can be achieved by bulk editing offers exciting opportunities for the therapeutic targeting
of these regions. Mechanistically, this region is a BCL11A binding site as described above
(45, 49), suggesting that deleting this element may abrogate the occupancy of this factor
and in turn allow for transcriptional activation.
Other HPFH variants map to a region between the g-globin and the adult 𝛿- and βglobin genes. This region contains the pseudogene HBBP1 and the non-coding gene
BGLT3 (54). Two HPFH variants are located within the second intron of HBBP1 (54). A
recent study showed that this region plays an important role in controlling higher-order
chromatin structure within the β-globin locus during these different developmental
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timepoints. Hi-C studies showed that the overall chromatin conformation of the locus is
very similar between fetal and adult stage, and that the HBBP1/BGLT3 region lies at a subTAD boundary (54). Finer resolution conformation capture studies by Capture-C showed
that during fetal stages the HBBP1/BGLT3 region interacts with two sites that flank the βglobin locus (HS5 and 3’HS1). This positions the LCR and the g-globin genes in the same
sub-TAD, thus favoring fetal hemoglobin expression. During adult stages, the
HBBP1/BGLT3 region interacts with the ε-globin promoter, thus preventing the LCR from
interacting with the g-globin genes. Deletion of the HBBP1/BGLT3 region lead to
transcriptional activation of g-globin, further supporting this region plays key roles in
regulating hemoglobin switching (54). Two recent studies showed that there is a strong
BCL11A binding site within this region (45, 49). The HBBP1/BGLT3 region was shown
to interact with HS5 and 3’HS1 upon BCL11A knockout in adult erythroid cells, further
suggesting that BCL11A may play a role in regulating the chromatin structure of the globin
locus through this element (54).
Several large deletions within the β-globin locus have also been shown to be associated
with high fetal globin levels in adulthood (55). The Corfu deletion is one such example,
and is proximal to the adult 𝛿-globin gene (31). There are also larger deletions removing
both the 𝛿- and β-globin genes identified in Sri-Lankan families who also show increased
levels of fetal hemoglobin (55). In contrast, a number of (𝛿β)0-thalassemia deletions have
been described that also involve both adult genes but do not show elevated HbF levels (55).
This may be due to the fact that these types of deletions do not involve the region
overlapping the Corfu deletion. ChIP studies have suggested that this region upstream of
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the 𝛿-globin promoter may be a BCL11A binding site (55), but how this element controls
the preferential expression of adult globins still remains to be fully elucidated.

1.3.2 Additional factors involved in fetal globin repression
While GWAS was instrumental in identifying regulators of fetal hemoglobin, other
factors that were not originally identified in these studies also appear to play roles in
regulating fetal hemoglobin. Recently, a study showed that the transcription factor
ZBTB7A, also known as LRF, is also a major repressor of fetal hemoglobin (56). LRF
knockout in murine models lead to a significant increase in either murine embryonic type
globins (56). Similarly, knocking out LRF in human erythroid cells, and knocking it down
in primary human erythroid cultures elevated HbF, though depleting this factor affects
erythroid maturation (56). LRF silences fetal hemoglobin independently of BCL11A as
double knockouts for these two factors show additive effects on HbF expression (56).
Mechanistically, LRF associates with members of the NuRD complex, but some of its cofactors are distinct from BCL11A (56). Recent chromatin immunoprecipitation studies
have shown that LRF occupies a regulatory element in the gamma-globin promoters (-200
cluster), which is upstream of the BCL11A binding site identified at the -115 cluster
(Figure 1.6) (49). These distinct occupancy patterns further support the fact that these two
factors operate independently of each other to repress fetal globin.
A number of other factors have also been implicated in HbF repression as well. The
transcription factor KLF1, which plays key roles in erythroid maturation, has been shown
to have HPFH variants mapping to it (31). Knockdown experiments in primary human
erythroid cultures have shown that depleting this factor leads to induction of fetal
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hemoglobin (57). This may be in part due to a reduction in BCL11A levels. It is possible
that KLF1 regulates BCL11A as it has been shown to occupy its erythroid specific
enhancer (31). These experiments though are confounded by the fact that KLF1 depletion
adversely affects erythroid maturation, but nonetheless implicate KLF1 in as playing a role
in globin switching.
The methyl-CpG binding domain MBD2 has also been implicated in repressing
fetal hemoglobin as knocking-out this factor in murine models leads to a robust induction
of embryonic type globins, and its knockdown in primary erythroid cultures leads to
significant HbF elevation (58). DNA methylation may play an important role in
maintaining the fetal globin genes in a repressed state as DNMT1 has also been shown to
play a role in this process (48), and BCL11A depletion leads to aberrant methylation within
the g-globin gene promoters (47). Several other transcriptional repressors have also been
implicated in this process including COUPTFII which occupies direct repeat elements in
close proximity to the CCAAT box at the -115 cluster of the g-globin promoters (31). It
still remains to be determined to what extent these factors specifically regulate the fetal
globin genes, and how they carry out these functions mechanistically.

1.4 Current efforts to raise HbF in adult patients
While treatments for hemoglobinopathies have improved over the past decades with
the use of antibiotic prophylaxis and bone marrow transplantation, these diseases still
remain challenging to manage clinically. Hydroxyurea is currently the only FDA-approved
drug for inducing HbF for these patients, its efficacy is still limited and mechanism of
action still unclear (59). A number of strategies are being pursued to develop improved
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treatment modalities for hemoglobinopathies. These either rely on the permanent
modification of HSCs, or pharmacologic approaches (60).

1.4.1 Gene therapy
Several gene therapy strategies are currently being developed and tested clinically
for the treatment of thalassemias and SCD. The first of these approaches relies on the
lentiviral transduction of a T87Q anti-sickling form of adult β-globin cassette in patientderived HSCs (61). The polymerization of sickle hemoglobin requires the incorporation of
two βS subchains in tetramers to interface with other sickle globin subchains in fibers.
Tetramers mixed for βS and a non-sickle β-type globin polymerize much less efficiently.
These antisickling effects are most pronounced for g- and 𝛿-globin as these have fewer
residues that can interact with βS-globin. Specific residues within the 𝛿-globin protein were
found to be most potent in conferring anti-sickling properties, which lead to the
development of the T87Q variant of β-globin which is very effective in preventing sickling
when overexpressed (61).
Several vectors have been developed to robustly express the T87Q β-globin variant
in vivo, and use a mini-LCR in tandem with the β-globin promoter to drive the expression
of this transgene to high enough levels to prevent red cell sickling. These vectors are
transduced into patient-derived HSCs which are then re-administered to patients by bone
marrow transplantation. The pharmaceutical company Bluebird Bio is now conducting
clinical trials to test the safety and efficacy of these approaches (drug product LentiGlobin
BB305) in small cohorts of SCD patients (62) and thalassemia patients (63). One treated
SCD patient experienced no sickle-related complications 15 months post-transplant and
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showed significant reduction in red cell sickling (62). In thalassemia patients, treatment
with the BB305 drug product lead to a significant or complete reduction in the need for
transfusions (63). No adverse complications due to vector integration have been reported
thus far, and further observation will be required to fully assess the safety profile of this
approach. Another gene therapy approach for the treatment of hemoglobinopathies uses a
vector expressing g-globin as a transgene (64). This was shown to be effective in a
humanized pre-clinical murine model of SCD by bone marrow transplantation. This
approach has yet to be tested clinically, but further demonstrates the potential for these
types of modalities.

1.4.2 Gene editing
As overviewed above, BCL11A is regulated by an enhancer in its second intron
that confers erythroid specific expression (50). Saturating mutagenesis screens have
narrowed down specific regions within this element required for its activity (51). Editing
these sites in HSCs would thus confer a permanent abrogation of BCL11A expression once
engrafted in patients by bone marrow transplantation. Phase I clinical trials led by
Vertex/CRISPR Therapeutics and Bluebird Bio are beginning this year to test the safety of
this approach. One important aspect to assess for these approaches will be off-target effects.
While CRISPR editing has been shown to have minimal off-target effects by GUIDE-seq
and CIRCLE-seq, it still remains to be determined to what extent these occur in vivo, and
whether any clonal events will occur. Furthermore, recent studies have shown that gene
editing may lead to the selection of p53 negative clones. P53 is normally activated in
response to double strand breaks to favor repair and block progression through the cell
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cycle. Cells that can progress with edits may be able to do so in part due to lower levels or
reduced function of this transcription factor (65). These will all be important aspects to
consider for these approaches, but nonetheless editing of the BCL11A erythroid specific
enhancer offers promising opportunities for the permanent correction of these diseases.

1.4.3 Pharmacologic approaches
Gene therapy and gene editing approaches offer exciting opportunities for the
treatment of hemoglobinopathies and are rapidly reaching the clinic. Non-myeloablative
conditioning regimens using CD117 (cKit) monoclonal antibodies to target recipient HSCs
are one example of how bone marrow transplantation approaches can further improve in
the short-term (66). But these methods still require significant resources which are still
currently not available to the global population of patients with hemoglobinopathies.
Pharmacologic agents are thus still needed to manage these diseases clinically.
Prior to hydroxyurea’s (HU) discovery as an HbF-inducing drug, the primary
compound known to induce HbF was the DNA methylase inhibitor 5-azacytidine which
reduces methylation of the fetal globin genes (67). Its off-target and cytotoxic effects
though prevented its clinical use. HU was first shown to elevate HbF levels in non-human
primate models approximately 30 years ago with limited cytotoxicity, and further shown
to have clinical benefits for patients with SCD (68). The mechanism of action of HU is still
unknown, though it has been proposed to induce HbF through cell cycle effects. HU is also
metabolized to nitric oxide which may ameliorate the vascular pathology seen with SCD
(67). HU is currently the only available FDA-approved drug for inducing HbF for patients
with SCD.
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Several other pharmacologic agents have been shown to induce HbF in erythroid
culture systems. One of these is the H3K9me1/2 histone methyltransferase
EHMT1/EHMT2 (also known as G9a) inhibitor UNC0638 (69). Treatment of erythroid
cells with this compound leads to an increase in HbF levels with little effect on erythroid
maturation. This was accompanied by a global decrease in H3K9me1/2 levels, including
at the fetal globin genes, with a reciprocal increase in H3K9ac. RNA-seq assays showed
that g-globin transcripts were amongst the most strongly increased, but also showed
broader perturbations to gene expression profiles upon treatment with UNC0638 (69). This
compound is now being developed for clinical purposed by Epizyme, and further work will
determine its safety, efficacy, and off-target profile in vivo.
Another compound recently shown to induce HbF levels is the drug pomalidomide
(70–72). A derivative of thalidomide, it is currently FDA-approved for the treatment of
multiple myeloma. It binds cereblon to activate its E3-ligase activity, which leads to
ubiniquination and proteasomal degradation of Ikaros and Aiolos (IKZF1 and IKZKF3,
respectively), which promotes cyotoxic effects in myeloma cells (72). Treatment of
erythroid cells with pomalidomide led to a significant increase in HbF levels (72). While
this led to a delay in early erythroid maturation at the BFU-E to CFU-E transition, later
stages of erythroid maturation were relatively unperturbed (72). Pomalidomide
downregulated a number of regulators of fetal hemoglobin, including a pronounced downregulation of BCL11A (72). The specificity of these effects and mechanisms underlying
them still remain to be determined, but may be independent of IKZF1/3.
A number of pharmacologic approaches have been identified to raise HbF levels for
the treatment of hemoglobinopathies. Given the rising global health burden that these
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diseases represent, there is still a strong need to develop improved small molecule
strategies for these types of disorders. In the next chapters, we will overview an approach
we have used towards this goal, showing how genetic screening approaches using CRISPRCas9 can be used to identify regulators of fetal hemoglobin that might serve as therapeutic
targets or combined with other known pharmacologic inducers to increase HbF levels.
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Figure 1.1 – Hematopoeitic tree from (60). Hematopoietic lineages arise from a
hematopoietic stem cell (HSC) which can self-renew and differentiate to a
Common Lymphoid Progenitor (CLP) which gives rise to lineages of the adaptive
immune system, and a Common Myeloid Progenitor (CMP). CMPs give rise to
lineages of the innate immune system through a Granulocyte-Macrophage
Progenitor (GMP), and to the erythroid and megakaryocyte linages through a
Megakaryocyte-erythroid progenitor (MEP). Erythroid differentiation is shown on
the left.
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Figure 1.2 – Timing of heme and globin production during erythroid maturation, from
(26). Stages of erythroid maturation are illustrated at the top. Surface marker expression
profiles during erythroid maturation are shown immediately below. Heme synthesis
begins early in erythroid maturation, and shortly thereafter is met with increased globin
production. There is a short window early in erythroid maturation where heme levels
exceed globin levels. In the context of disorders affecting globin protein synthesis by
impairment of the translational machinery such as DBA and 5q minus MDS, globin
synthesis does not match heme levels and this leads to impaired erythropoiesis.
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Figure 1.3 – Organization of the β-globin locus and hemoglobin switching (31).
The β-globin locus encodes multiple β-type globin genes that are expressed during
specific developmental time frames. These genes are regulated by a regulatory
element termed the Locus Control Region (LCR) that lies upstream of the locus.
The fetal type genes are primarily expressed during gestation. Shortly after birth
expression shifts to adult type genes. In most adults HbF constitutes only 0.5% of
total β-type globin synthesis. There is however natural variation in the extent to
which HbF is silenced in adulthood, which has important clinical implications in
the context of genetic disorders that affect adult type globin genes, such as βthalassemia and SCD.

32

Figure 1.4 – HbF levels and survival outcomes for SCD patients (41). These results
were obtained from an observational study of SCD patients who were stratified into
2 groups as either having high levels of HbF (above 8.6%) and low levels of HbF
(below 8.6%). Survival outcomes are shown for each group. High levels of HbF
are associated with significantly improved survival outcomes for these SCD
patients groups.
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Figure 1.5 – GWAS for HbF as a quantitative trait from (42). These studies
identified 3 loci with variants associated with high HbF levels: HBS1L-MYB,
BCL11A and the β-globin locus.
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Figure 1.6 – Model for repression of fetal globin genes by BCL11A and LRF,
adapted from (47), BCL11A and LRF occupy multiple regions within the globin
locus to silence fetal globin genes, including by direct occupancy of their
promoters.
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CHAPTER 2: MATERIALS AND METHODS
Cell culture
HUDEP2 cells were cultured as described (73). Cells were maintained in StemSpan™
Serum Free Medium (SFEM, StemCell Technologies, Cat. #09650) supplemented with
50ng/ml human Stem Cell Factor (hSCF, Peprotech, Cat. #300-07), 10µM
dexamethasone (Sigma, Cat. #D4902), 1µg/ml doxycycline (Sigma, Cat. #D9891),
3IU/ml erythropoietin (Amgen, Cat. #55513-144-10), 1% penicillin/streptomycin
(ThermoFisher, Cat. #15140122). Cells were kept at a density of less than 1.0 million/ml.
Differentiation was achieved by growing cells for 7 days (one medium change at day 3 or
4) in IMDM (Mediatech, Cat. #MT10016CV) supplemented with 50ng/ml hSCF, 3IU/ml
erythropoietin, 2.5% fetal bovine serum, 250µg/ml holo-transferrin (Sigma, Cat.
#T4132), 1% penicillin/streptomycin, 10ng/ml heparin (Sigma, H3149), 10µg/ml insulin
(Sigma, Cat. #I9278), 1µg/ml doxycycline.

CD34+ cultures. Peripheral blood mononuclear cells (PBMCs) were obtained from the
University of Pennsylvania Human Immunology Core. CD34+ cells were purified from
using MACS MicroBead kit (Miltenyi, Cat #130-100-453) and cultured in three phases in
IMDM supplemented with 3IU/ml erythropoietin, 2.5% human male AB serum (Sigma,
Cat. #H4522), 10ng/ml heparin, 10µg/ml insulin. Phase-I medium was supplemented with
100ng/ml hSCF, 5ng/ml IL-3 (Peprotech, Cat. #200-03), 250µg/ml holo-transferrin. PhaseII medium was supplemented with 100ng/ml hSCF and 250µg/ml holo-transferrin. PhaseIII medium was supplemented with 1.25mg/ml holo-transferrin. Cells were maintained in
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Phase-I from the day of collection until day 8. Cells were spin-infected (see virus
preparation and infections below for full details) and transitioned to Phase-II media, and
finally transitioned to Phase-III media on day 13 of culture. RNA samples for RT-qPCR
were harvested on day 13 of culture for optimal RNA yield. Western Blot, HPLC, and HbF
FACS samples were harvested on day 15 of culture.

Cell lines for sgRNA-scaffold optimization. A-375 cells were cultured in DMEM, HCT116
and A549 cells were cultured in DMEM/F-12, K562 cells were cultured in RPMI1640. All
cell lines used in this study were mycoplasma free.

Plasmids
The Cas9 expression vector was constructed by inserting the 5′-3xFLAG-tagged
human-codon optimized Cas9 cDNA from Streptococcus pyogenes (Addgene: #49535)
into a lentiviral EFS-Cas9-P2A-Puro expression vector using the In-Fusion cloning system
(Clontech: #638909). All sgRNA encoding oligonucleotides were inserted into a lentiviral
U6-sgRNA-EFS-GFP expression vector (LRG, Addgene: #65656) using a BsmBI
restriction site. Oligonucleotides corresponding to the shRNAs were annealed and cloned
into the same vector as were sgRNAs with the sgRNA scaffold removed by a BsmBIEcoRI double digestion resulting in LRG-U6-shRNA-EFS-GFP. See Table S4 for a list of
shRNA sequences used for this study.

Virus preparation and infections
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Virus was produced in HEK293T cells grown in DMEM supplemented with 10%
Fetal Bovine Serum, 2% penicillin/streptomycin, 1% L-glutamine, 100µM sodium
pyruvate. HEK293Ts were plated in 10cm plates 18-24h prior to transfection such that cells
were 90-100% confluent by the time of transfection. Expression vectors were mixed in a
4:3:2 ratio with packaging plasmids, PAX2, and VSVG envelope plasmid, respectively, in
500µl OPTI-MEM (ThermoFisher Scientific, Cat #31985070), and added to 500ul of
160µg/ml polyethylenimine (PEI, Polysciences Cat. #23966) in OPTI-MEM for
precipitation. Plasmid precipitations were added to HEK293T cells and transfections were
incubated at 37°C, 5% CO2 for 6 hours, after which fresh media was placed on the cells.
Viral supernatants were harvested 24 hours and 48 hours post-transfection and pooled.
One million HUDEP2 cells were infected with Cas9- or single sgRNA-containing
virus by spin-infection with 1ml of viral supernatant supplemented with 8µg/ml polybrene
and 10mM HEPES buffer. Spin-infections were carried out at 2,250 rpm for 1.5 hours at
room temperature in 12-well plates. HUDEP2-Cas9 cells were selected starting 48-hours
post-infection for 5 days in 1µg/ml puromycin. sgRNAs were transduced consistently
above 90% GFP+ levels. See below for full details on transductions for the kinase domain
sgRNA-library.
For infection of primary CD34+ derived erythroid cells with shRNA containing virus,
viral particles required concentration due to lower infectivity of these cells. Viral
supernatants were concentrated with LentiX-concentrator (Clontech, Cat. #631232) per
manufacturer specifications. Viral pellets were resuspended in Phase-I media. Cells were
spin-infected with concentrated virus from one 10cm plate (24-hour and 48-hour viral
supernatants pooled) supplemented with 8µg/ml polybrene and 10mM HEPES per 1
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million cells. Spin-infections were carried out at 2,250rpm for 1.5 hours at room
temperature in 12-well plates, followed by incubation at 37°C, 5% CO2 overnight. Cultures
were then transitioned to Phase-II media.

TIDE analysis
CRISPR-Cas9 targeted regions were amplified by PCR from genomic DNA
(gDNA) from HUDEP2 cells transduced with a sgRNA, as well as from an uninfected
HUDEP2 control cell line. Primers were designed to flank targeted regions 250-300bp on
either side. Amplifications were done with AccuPrime™ Pfx Supermix (ThermoFisher
Scientific Cat. #12344040) per manufacturer specifications. Amplicons were purified with
the QIAquick PCR purification kit (Qiagen, Cat. #28106), and Sanger sequenced at the
Children’s Hospital of Philadelphia sequencing core (NAPCore facility). Sequencing
chromatograms were analyzed with the TIDE R-package (74). See Table S5 for a list of
primers used for TIDE.

HbF flow cytometry and FACS
For HbF analysis cells were fixed in 0.05% glutaraldehyde for 10min, washed 3
times with PBS/0.1%BSA (Sigma, Cat. #A7906), and permeabilized with 0.1% Triton X100 (Life Technologies Cat. #HFH10, prepared in PBS/0.1%BSA) for 5 minutes.
Following one wash with PBS/0.1% BSA, cells were stained with HbF-APC conjugate
antibody (Invitrogen, Cat. #MHFH05). For HUDEP2 samples, 2 to 5 million cells were
incubated with 2µg HbF-APC antibody for 30 minutes in the dark at room temperature.
For primary CD34+ erythroid cells, 2 to 5 million cells were incubated with 0.4µg HbF-
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APC antibody for 10 minutes in the dark at room temperature. Cells were then washed
twice with PBS/0.1%BSA. Flow cytometry was carried out on a BD FACSCanto™ and
cell sorting on a BD FACSJazz™ at the Children’s Hospital of Philadelphia flow cytometry
core.

Kinase domain-focused CRISPR sgRNA library construction
A comprehensive human kinase gene list was taken from a previous study (14), and
catalytic enzymatic domains retrieved from the NCBI database of conserved domain
annotations. sgRNAs were designed against 496 kinase domains of 482 kinase genes, with
6 sgRNAs per domain. 26 sgRNAs targeting essential genes and 50 non-targeting sgRNAs
were spiked-in as positive and negative controls, respectively. In total, the library contains
3052 sgRNAs. All the sgRNAs were designed using design principles previously reported
and were filtered based on predicted off-target effects (75). sgRNAs were synthesized in a
pooled format on an array platform (Twist Bioscience) and then PCR cloned into the LRG
vector with sgRNA2.1 backbone (LRG 2.1 vector, see Supplementary Text for full
description). To ensure proper representation of sgRNAs in the pooled lentiviral plasmids,
the library was analyzed by deep-sequencing on a MiSeq instrument (Illumina), which
confirmed that 100% of the designed sgRNAs were cloned in the LRG2.1 vector with over
95% of sgRNAs being within 5-fold of the mean read count (data not shown).

CRISPR-Cas9 screen
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The kinase domain-focused sgRNA library was packaged in lentivirus as indicated
above. Viral titer was determined by serial dilution. HUDEP2-Cas9 cells were transduced
with the kinase-domain library at a low multiplicity of infection (MOI 0.3-0.5) such that
30 to 50% of cells were GFP positive (MOI for these studies was of ~0.4, see Fig. S2E). 9
million cells were infected in total to yield 1000x coverage of the sgRNA library in the
GFP+ population. GFP+ cells were sorted by FACS on day 2 post-infection.
GFP+ cells were then cultured in HUDEP2 media (as indicated above) for an
additional 6 days (total 8 days post-infection). On day 8 post-infection, cells were
transitioned to differentiation media (as indicated above), and differentiated for 7 days.
On day 15 post-infection, cells were stained for HbF as indicated above, and sorted into
HbF high and HbF low populations (see Fig. 1B) as previously described (51).
Genomic DNA (gDNA) was harvested from these samples by phenol/chloroform
(Fisher Scientific Cat #BP1752I-100) extractions per standard methods. sgRNAs were
amplified with Phusion Flash High Fidelity Master Mix Polymerase (ThermoFisher
Scientific, Cat. #F-548L) per manufacturer specifications with the LRG F2/R2 primer pair
(see Table S6). Reactions were done with 23 cycles of amplification with 100ng of gDNA,
and 50 parallel reactions were performed to maintain sgRNA library representation. PCR
reactions were then pooled for each sample and column purified with QIAGEN PCR
purification kit. PCR products were subjected to Illumina MiSeq library construction and
sequencing. First, PCR products were end repaired with T4 DNA polymerase (New
England BioLabs, NEB), DNA polymerase I (NEB), and T4 polynucleotide kinase (NEB).
Then, an A-overhang was added to the end-repaired amplicons using Klenow DNA Pol
Exo- (NEB). The A-overhang DNA fragment was ligated with diversity-increased
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barcoded Illumina adaptors followed by seven pre-capture PCR cycles with primer pair
PE-5/PE-7 (see Table S6). Samples were then purified with the QIAquick PCR purification
kit. sgRNA library concentrations were quantified on a 2100 Bioanalyzer (Agilent). The
barcoded libraries were pooled at an equal molar ratio and subjected to massively parallel
sequencing through a MiSeq instrument (Illumina) using 75-bp paired-end sequencing
(MiSeq Reagent Kit v3; Illumina MS-102-3001).
The sequencing data were de-barcoded and trimmed to contain only the sgRNA
sequence, and subsequently mapped to the reference sgRNA library without allowing any
mismatches. The read counts were calculated for each individual sgRNA and normalized
to total read counts. Normalized read counts of sgRNAs in HbF high and HbF low
populations were log2 transformed in R, and graphical representation was done using the
R-package ggplot2.

Western Blot
Western blotting was performed using standard procedures. Primary antibodies: HRI
(1:1000, Biosource, Cat. #MBS2526743), eIF2α-Phospho (1:1000, anti-EIF2S1-phosphoS51, Abcam, Cat. #ab32157), total-eIF2α (1:1000, Cell Signaling, Cat. #9722), BCL11A
(1:1000, Abcam, Cat. #19489), LRF (1:1000, eBioscience Cat. #), GATA1 (1:1000, Santa
Cruz, Cat. #sc-265), g-globin (1:1000, Santa Cruz, Cat. #sc-21756), B-actin (1:1000, SantaCruz, Cat. #sc-47778). Secondary antibodies: anti-rabbit (1:10,000, GE Healthcare, Cat.
#NA934V); anti-mouse (1:10,000, GE Healthcare, Cat. #NA931V).

RT-qPCR
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RNA samples were harvested in TRIzol™ (ThermoFisher Scientific, Cat #15596018),
and purified with the RNeasy Mini kit which included an on-column DNAse treatment to
remove genomic DNA (Qiagen, Cat. #74106). cDNAs were prepared by reversetranscription using iScript Supermix (Bio-Rad, Cat. #1708841). qPCR reactions were
prepared with Power SYBR Green (ThermoFisher Scientific) and run on a ViiA7 Real
Time qPCR machine (ThermoFisher Scientific). Quantification was performed with the
ΔΔCT method. Primers used for RT-qPCR are listed in Table S7.

RNA-seq
Total RNA was harvested in TRIzol™, and purified with the RNeasy Mini kit
including a DNase treatment step to remove genomic DNA. Sequencing libraries were then
constructed from 100 ng of purified total RNA using the ScriptSeq Complete Kit (Illumina
cat# BHMR1224) according to manufacturer’s specifications. In brief, the RNA was
subjected to rRNA depletion using the Ribo-Zero removal reagents and fragmented. First
strand cDNA was synthesized using a 5’ tagged random hexamer, and reversely
transcribed, followed by annealing of a 5’ tagged, 3’-end blocked terminal-tagged oligo for
second strand synthesis. The Di-tagged cDNA fragments were purified, barcoded, and
PCR-amplified for 15 cycles.
The size and quality of each library were then evaluated by Bioanalyzer 2100 (Agilent
Techniologies, Santa Clara, CA), and quantified using qPCR. Libraries were sequenced in
paired-end mode on a NextSeq 500 instrument to generate 2 x 76 bp reads using Illuminasupplied kits. The sequence reads were processed using the ENCODE3 long RNA-seq
pipeline (https://www.encodeproject.org/pipelines/ENCPL002LPE/). In brief, reads were
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mapped to the human genome (hg19 assembly) using STAR, followed by RSEM for gene
quantifications. Read counts were further analyzed with the R-package DESeq2.

Proteomics analysis via nLC-MS/MS
Cells were lysed in 100µl of cold lysis buffer (6M urea/2M thiourea, 50 mM
ammonium bicarbonate, pH 8.0). Dithiothreitol (DTT) was added to a final concentration
of 5 mM for 1 hour at room temperature and alkylated with 20 mM iodoacetamide in the
dark for 30 minutes at room temperature. Samples were diluted 5x to reduce urea
concentration. Proteins were then digested with trypsin (Promega) at an enzyme-tosubstrate ratio of approximately 1:50 overnight at room temperature. Digestion was
interrupted by adding 1% trifluoroacetic acid. Samples were desalted using Sep-Pak tC18
Plus Light Cartridge (Waters). The peptide samples were subsequently lyophilized.
Dried samples were resuspended in buffer A (0.1% formic acid) and loaded onto an
Easy-nLC system (Thermo Fisher Scientific, San Jose, CA, USA), coupled online with a
Q-Exactive mass spectrometer (Thermo Scientific). Peptides were loaded into a picofrit 18
cm long fused silica capillary column (75 µm inner diameter) packed in-house with
reversed-phase Repro-Sil Pur C18-AQ 3 µm resin. A gradient of 105 minutes was set for
peptide elution from 2-28% buffer B (100% ACN/0.1% formic acid), followed by a
gradient from 28-80% buffer B in 5 min and an isocratic 80% B for 10 min. The flow rate
was 300 nl/min. The MS method was set up in a data-dependent acquisition (DDA) mode.
The full MS scan was performed at 70,000 resolution (FWHM at 200 m/z) in the m/z range
360-1200 and an AGC target of 10e6. Tandem MS (MS/MS) was performed at a resolution
of 17,500 with an HCD collision energy set to 24, an AGC target of 2x10e4, a maximum
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injection time to 100 msec, a loop count of 10, an intensity threshold for signal selection at
10e4, including charge states 2-4, and a dynamic exclusion set to 60 sec.
MS raw files were analyzed by MaxQuant software (76) version 1.5.5.1. MS/MS
spectra were searched by the Andromeda search engine against the Human UniProt
FASTA database (version November 2015). All parameters for the search were kept as
default. Intensity-based absolute quantification (iBAQ) (76) was enabled for label-free
quantification. Match between runs was enabled and set to 1 min window.
For data analysis, iBAQ values were log2 transformed and normalized by subtracting
to each value the average value of the respective sample. Statistics was performed by using
a two-tails homoscedastic t-test.

Hemoglobin HPLC
Cell were lysed in MilliQ H2O. Hemolysates were cleared by centrifugation and
analyzed for identity and levels of hemoglobin variants (HbF and HbA) by cation-exchange
high-performance liquid chromatography (HPLC). We utilized a Hitachi D-7000 Series
(Hitachi Instruments, Inc., San Jose, CA), and a weak cation-exchange column (Poly CAT
A: 35 mm x 4.6 mm, Poly LC, Inc., Columbia, MD). Hemoglobin isotype peaks were
eluted with a linear gradient of phase B from 0% to 80% at A410nm (Mobile Phase A: 20
mM Bis-Tris, 2 mM KCN, pH 6.95; Phase B:20 mM Bis-Tris, 2 mM KCN, 0.2 M sodium
chloride, pH 6.55). Cleared lysates from normal human cord blood samples (high HbF
content), as well as a commercial standard containing approximately equal amounts of
HbF, A, S and C (Helena Laboratories, Beaumont, TX), were utilized as reference isotypes.
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Sickling assay
Cells were resuspended in 100µL HEMOX buffer supplemented with glucose (10
mM) and BSA (0.2 %) in a 96-well plate. Suspensions were subsequently incubated under
Nitrogen gas at 37°C for 1 hour. 200µL of 2% glutaraldehyde solution was then added to
the samples without exposure to air for immediate fixation. Fixed cell suspensions were
spread onto glass microslides (Fiber Optic Center) and subjected to microscopic
morphological analysis of bright field images (at 40x magnification) of single layer cells
on an Olympus BX40 microscope fitted with an Infinity Lite B camera (Olympus), and the
coupled Image Capture software. Images were randomized and blinded. The percentage of
sickled cells for each condition was obtained by manually counting the number of sickled
cells.

Wright-Giemsa stains
Cells were spun onto glass slides with a Cytospin4 (ThermoFisher Scientific,
Cat#A78300003) at 1,000rpm for 3 min. Slides were allowed to dry for 5 minutes before
staining with May Grünwald (Sigma Aldrich, MG1L-1L) for 2 minutes followed by 1:20
diluted Giemsa stain (Sigma Aldrich, GS-500 500ML) for 10 minutes. The stained slides
were rinsed in water and allowed to dry for 10 minutes before a coverslip was sealed on
the preparation with Cytoseal 60 (Thermo Scientific Cat #8310-4). The images were
captured at 10X resolution on Olympus BX60 microscope using Infinity software
(Lumenera corporation).
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Polysome profiling
Cells were arrested in Phase II media with 100ug/ml cycloheximide (Sigma
CC4859) for 15 minutes at 37C. Cells were then washed twice in ice cold 1x PBS with
100ug/ml cycloheximide, and resuspended in 500ul lysis buffer (10mM Tris-HCl (pH 7.4),
5mM MgCl2, 100mM KCl, 1% Triton X-100, 2mM DTT, 500U/mL RnasinPlus (Promega
N2615), protease inhibitor cocktail (Sigma 11873580001)). Lysates were then dounced
with a 26G needle 5 times, and cellular debris were cleared by centrifugation at 13,000rpm
for 10 minutes. 10% of cleared lysates were set aside for input mRNA quantitation, and
samples were snap-frozen in liquid nitrogen.
Cleared polysomal lysates were loaded on sucrose gradients and spun at 40,000rpm
for 2 hours at 4C (Beckman SW41 rotor). Sixteen fractions of equal volume (~700ul) were
collected and gradient profiles were measured by ultraviolet absorbance at 254nm with a
UA-5 detector (ISCO). Fractions were incubated with 1% SDS and proteinase K for 30
minutes at 37C, and stored at -80C until further analysis.
RNA was purified from fractions by phenol-chloroform extraction. ERCC spike-in
RNA was added to each fraction (1ul of 1:10 dilution of spike-in control per fraction,
ERCC-spike in (ThermoFisher, 4456740)). 400ul of phenol (Phenol/Water 3.75:1
Invitrogen Cat. # 15594-047) was added to each fraction. Samples were vortexed for 30
seconds. 350ul of chloroform (ThermoFisher, Cat. #BP1145-1) was added, and samples
were vortexed again for 30 seconds. Samples were spun down at 10,000rpm for 10 minutes,
and aqueous layers were transferred to fresh tubes. One additional round of phenolchloroform extractions were performed. Aqueous phases were split into two tubes with
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350ul of sample each. 1.5ul of glycogen carrier, 30ul of 3M sodium acetate pH 5.5
(ThermoFisher, Cat. #AM9740) and 800ul of ice cold 100% ethanol were added to each
final aqueous phases, and place at -80C overnight. RNA was precipitate by spinning
samples at 13,000rpm for 30 minutes at 4C. Pellets were washed with 1mL of 75% ethanol,
and RNA was resuspended in nuclease-free water. cDNAs were prepared using iScript
Supermix (Bio-Rad, Cat. #1708841). qPCR reactions were prepared with Power SYBR
Green (ThermoFisher Scientific) and run on a ViiA7 Real Time qPCR machine
(ThermoFisher Scientific).

BCL11A cDNA rescue experiments
The BCL11A cDNA was a gift from Jian Xu (UT Southwestern) and subcloned
into a lentiviral LRG-EFS-BCL11A-IRES-mCherry vector by In-Fusion cloning. Virus
was prepared and transduced in respective cell lines as indicated above. To control for
expression levels, the low 50% mCherry+ cells were sorted on a BD FACSJazz™ at the
Children’s Hospital of Philadelphia flow cytometry core. Cells were differentiated and
analyzed as indicated above.

Mouse fetal liver cultures
E14.5 mouse fetal livers were obtained from CD1 pregnant females (Charles River strain
code 022, req #V00018219:1, IACUC protocol #660). The EasySep™ Mouse
Hematopoietic Progenitor Cell Enrichment Kit (Stem Cell Technologies cat. #19756) was
used for hematopoietic progenitor isolation. Cells were transduced with shRNAs per
spinfection protocol detailed above. Transduced cells were cultured for 48h in StemPro34
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with supplement (Thermo Fisher cat #10639011), 1% L-glutamine, 1% P/S, 0.5U/ml
erythropoietin, 1µM dexamethasone. Cells were harvested for RT-qPCR and Western Blot
as indicated above.

Pomalidomide combination experiments
HUDEP2 cells were incubated with 10µM pomalidomide (Sigma, Cat. # P0018)
for 2 days. Cells were then transitioned to differentiation media as indicated above for 7
days. During the course of differentiation cells were maintained in 10µM pomalidomide.
Media was changed 3 to 4 days within the differentiation phase with fresh drug
supplemented. HbF FACS and RT-qPCR were performed as indicated above.
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CHAPTER 3: DOMAIN-FOCUSED CRISPR-SCREEN
IDENTIFIES HRI KINASE AS A REGULATOR OF FETAL
HEMOGLOBIN IN ADULT ERYTHROID CELLS

3.1 Chapter summary
Research described in this chapter was carried out in collaboration with the
laboratory of Dr. Junwei Shi who designed and executed the sgRNA and Cas9 plasmid
cloning, sgRNA scaffold optimization, sgRNA library construction and viral packaging.
Xianjiang Lan, Nicole Hamagami, Laavanya Sankaranarayanan, Christopher E. Edwards,
Saurabh Bhardwaj, and Carolyne Face executed experiments. Dave Posocco, Osheiza
Abdulmalik, and Stella Chou carried cultures and assessment of sickle derived primary
cultures. Simone Sidoli and Ben Garcia performed mass spectrometry and downstream
analysis. Cheryl Keller, Belinda Giardine and Ross Hardison executed RNA-seq and read
alignment. Xinjun Ji and Stephen A. Liebhaber helped design and perform the polysome
profiling experiments.
The work described here forms the body of a manuscript that was published prior
to the writing of this dissertation in Science (2018) with the following reference:
Grevet, J., Lan, X., Hamagami, N., Edwards, C., Sankaranarayanan, L., Ji, X., Bhardwaj,
S., Face, C., Posocco, D., Abdulmalik, O., Keller, C., Giardine, B., Sidoli, S., Garcia, B.,
Chou, S., Liebhaber, S., Hardison, R., Shi, J. & Blobel, G. (2018). Domain-focused
CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid
cells. Science 361(6399), 285–290.
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3.2 Introduction
The human b-globin gene cluster comprises an embryonic (e-globin), two fetal (gglobin) and two adult type (d-globin and b-globin) genes (31). Diseases affecting the adult
type b-globin genes, such as sickle cell disease (SCD) and some types of b-thalassemia
manifest themselves after birth following the transition from fetal to adult hemoglobin
production. The clinical course of these diseases is ameliorated when fetal hemoglobin
(HbF) levels are elevated because of genetic causes or medical intervention (41). Genome
wide association studies (GWAS) have identified three major loci that are linked to natural
variation in HbF levels, including the transcription factor BCL11A (31). Patients with
heterozygous loss of BCL11A exhibit elevated HbF levels throughout adult life (77), and
BCL11A depletion in cultured human erythroid precursors raises HbF production (44, 46).
Loss of BCL11A in engineered mice that express human sickle hemoglobin stimulates fetal
globin expression and ameliorates their disease phenotype (47).
Strategies to achieve long-term elevation of HbF levels in patients include gene
therapy to force the expression of g-globin, and gene editing to impede BCL11A expression
(50, 64). Current clinical risks, costs, and availability limit such therapies to a fraction of
the patient population. The only FDA-approved drug to raise HbF is hydroxyurea which
benefits many patients but is limited in its efficacy (59). Hence there is a need for
pharmacologic approaches to increase HbF levels.
Two transcription factors, BCL11A and LRF (ZBTB7A) and their co-regulators
mediate most of g-globin transcriptional silencing in adult erythroid cells (56). However,
transcription factors are inherently challenging to inhibit with small molecules. We carried
out a CRISPR/Cas9 screen to target protein kinases, because in principle, they are
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inherently controllable by small molecules (78). It has recently been shown that targeting
sgRNAs to functional protein domains can significantly improve screening efficiency, as
both in-frame and frameshift mutations contribute to generating hypomorphic alleles (79).
We designed a library of sgRNAs targeting 482 kinase domains (6 sgRNAs per kinase, and
50 non-targeting sgRNAs as negative controls), which covers almost all annotated kinases
in the human genome (78).

3.3 Screen optimization
Prior to performing the screen, we optimized the Streptococcus Pyogenes Cas9
sgRNA-scaffold for on-target activity (see Supplementary Text for details). This sequence
adopts a well-defined secondary structure, with a repeat-antirepeat duplex linked to a
tetraloop and 3 stem loops, all of which facilitate binding to Cas9 and stabilize the sgRNA
(Fig. S1A,B) (80). Previous work showed that an A-U flip in the repeat-anti-repeat duplex
removes a putative premature Pol-III stop codon, and that extending the tetraloop
significantly improved sgRNA stability and Cas9 activity (81). By examining the Cas9
crystal structure, we noticed that stem loop 2 forms few contacts with Cas9 residues,
similar to the tetraloop (80). Mutations in stem loop 2 are also well tolerated and allow for
efficient Cas9 activity (80). We thus reasoned that extending stem loop 2 could further
improve sgRNA stability similar to what had been done for the tetraloop, as this could
further increase the double-stranded portion of the scaffold (Fig. S1B). We compared
different lengths of such extensions (sgRNA 2.0 – sgRNA2.3).
To do so, we performed negative selection assays using the bicistronic sgRNA/GFP
expression vector detailed above (LRG, Addgene: #65656). Cell lines were transduced
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with sgRNAs targeting essential genes such that selection against the sgRNAs would
directly reflect editing efficiency for the different sgRNA scaffold designs. Negative
selection was estimated by taking the proportion of GFP+ cells remaining over time (flow
cytometry analysis was performed on 96-well plates of cells using a Guava Easycyte HT
instrument (Millipore), gating was performed on live cells (using forward and side scatter),
before measuring of GFP+ cells) (Fig. S1C,D). We found that an extended hairpin structure
in both tetraloop and stem loop regions of the sgRNA backbone (termed sgRNA2.1)
significantly improved the magnitude of negative selection in various human cell lines
induced by sgRNAs targeting DNA replication proteins RPA3 and PCNA (Fig. S1C,D).
We then tested the modified scaffold design in HUDEP2 cells, a human erythroid
cell line with low HbF background levels (See Materials and Methods for full details)
(73) which we used to perform the kinase domain screen (Fig. S2A). Control sgRNAs
targeting the known HbF regulators BCL11A and the chromatin remodeler CHD4 (48),
were introduced via lentivirus into engineered HUDEP2 derivatives stably expressing
Cas9 (HUDEP2-Cas9, see Materials and Methods for full details). Indel distributions
were assessed by TIDE (see Materials and Methods for full details) (74). In the context of
the sgRNA 2.1 template we achieved up to 98% editing efficiency as early as 4 days
post-infection (Fig. S2B) with most sequence perturbations being deletions of less than
10 base pairs (Fig. S2C). As expected, targeting BCL11A increased the number of HbF
positive cells (51). Based on these results, we used the sgRNA 2.1 design for all
subsequent CRISPR-based experiments.
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sgRNA2.1 emerged as the most efficient in mutagenizing target loci in multiple cell
lines, achieving up to 98% genome editing efficiency as early as 4 days following
introduction into cells (Fig.S1 and Fig.S2). We cloned the kinase-domain sgRNA library
into the sgRNA2.1 scaffold and introduced it into HUDEP2 cells stably expressing Cas9
(Figure 1A). HUDEP2 is an immortalized human cell line that can be induced to undergo
erythroid differentiation and produce high levels of adult and low levels of fetal type
hemoglobin (13). We used anti-HbF FACS to isolate the top 10% and bottom 10% HbF
expressing cells (Fig. 1A,B) and deep sequenced sgRNAs as described previously (51).
Non-targeting control sgRNAs were similarly distributed across HbF low and high
populations, indicating that the screen did not bias the enrichment in either direction (Fig.
1C).
3.4 Kinase-domain CRISPR screen identifies HRI as a potential regulator of fetal
hemoglobin
Heme-regulated inhibitor HRI (also known as EIF2AK1) was the only kinase for
which all targeting sgRNAs were overrepresented in the HbF high population (Fig. 1C).
HRI is one of four kinases known to phosphorylate the protein translation initiation factor
eIF2α (Fig. S3) (28). Phosphorylation of eIF2α generally impedes mRNA translation, but
enables the translation of transcripts that include one or more upstream open reading frames
(uORFs) in their 5’ untranslated regions. HRI is enriched in erythroid cells where it can be
inhibited by its natural ligand heme (Fig. S4A,B). It is thought that this regulation balances
heme levels with production of globin chains, as excess of either of these can be detrimental
(28). The other eIF2α kinases are expressed at significantly lower levels in erythroid cells
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(Fig. S4C). While small molecules have been developed against other members of the
eIF2α kinase family, effective HRI-specific inhibitors are lacking.
3.5 Validation of HRI as a fetal hemoglobin regulator in HUDEP2 cells
We validated HRI as a HbF regulator by expressing all six “hit” sgRNAs (Fig. S5)
individually in HUDEP2-Cas9 cells, along with a sgRNA against BCL11A as a
benchmark, and a non-targeting sgRNA as a negative control. All six HRI targeting
sgRNAs increased the fraction of HbF+ cells (Fig. 2A,B). Cells expressing HRI sgRNAs
#3 and #5 were studied by Western blot, which revealed that the sgRNAs achieved strong
depletion of HRI resulting in decreased eIF2α phosphorylation, and significantly increased
g-globin protein levels (Fig.2C). There were no changes in the protein levels of GATA1,
suggesting that HRI loss did not impair cell maturation (Fig. 2C).

EIF2α phosphorylation is thought to broadly control protein translation, suggesting
that HRI inhibition might lead to widespread changes in protein levels and secondary
changes in gene expression. We measured protein abundances in undifferentiated and
differentiated HRI-depleted HUDEP2 pools for sgRNA#3 and #5 by replicate whole cell
mass spectrometry studies (see Fig. S6 A-C). Notably, protein amounts were changed
relatively little in HRI-depleted differentiated HUDEP2 cells (Fig. 2D, Fig. S7A-D), and
g-globin was one of the most induced proteins (Fig. 2D, Fig. S7A, Table S1). We did
observe a modest rise in global protein levels, perhaps due to a non-specific augmentation
in protein translation resulting from lower eIF2α phosphorylation (Fig. S7A,B). Whole cell
mass spectrometry detected the ~2000 and ~2500 most abundant proteins in differentiated
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and undifferentiated samples, respectively. Thus, it is possible that significant changes
were missed among low abundance proteins. Nevertheless, overall the effects of HRI
depletion were unexpectedly specific for g-globin.

In parallel, we carried out replicate RNA-seq experiments (see Fig. S8A) in
differentiated HRI depleted HUDEP2 pools for sgRNA#3 and #5 and found that global
transcript distributions were relatively unperturbed (Fig. 2E). g-globin mRNA stood out as
the most significantly induced in differentiated cells (Fig. 2E, Fig. S8B, Table S1). RTqPCR experiments confirmed the effects on g-globin mRNA and primary transcripts,
suggesting that HRI depletion increases g-globin transcription (Fig. S9A,B). We did not
observe any noticeable changes in α-globin, ALAS2, BAND3 and GATA1 mRNAs (Fig.
S9C), suggesting that erythroid differentiation is essentially normal in HRI deficient cells.
These results were further validated in two independent clonal HRI depleted cell lines
generated from the HRI sgRNA#5 pool (Fig. S10A-E).

3.6 Validation of HRI as fetal hemoglobin regulator in primary CD34+ derived
erythroid cultures
HRI’s role as a HbF repressor was further tested in primary erythroblasts derived
from a three-phase human CD34+ culture system (see Materials and Methods). We
depleted HRI with two independent shRNAs. For comparison, we used the strongest
shRNAs against LRF amongst two previously published (56). We verified transduction
levels by GFP flow cytometry (Fig. S11A). Both HRI shRNAs significantly increased the
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proportion of HbF+ cells (Fig. 3A, B). The proportion of g-globin mRNA as a percentage
of total globin transcripts was also significantly increased upon HRI knockdown (Fig. 3C).
RNA-seq in cells with either shRNA demonstrated that the increases in g-globin
mRNA was among the most significant changes (Fig. 3D), similar to the results in
HUDEP2 cells, with global transcript distributions for HRI knockdown samples being
strongly correlated with those from the scrambled shRNA (Fig. 3D). Similar elevation of
HbF was detected at the protein level as measured by HPLC (Fig. 3E, note donor to donor
variation in the human culture system). HRI depletion did not appear to delay the
maturation of these cells, as evidenced by similar transcript levels for maturation markers
(Fig. 3D), cell surface markers CD71 and CD235a (Fig. S11B), and cell morphology (Fig.
S11C).

Elevated HbF levels counteract sickling of cells expressing sickle hemoglobin
(HbS) (31). To assess whether HRI depletion elicits anti-sickling effects, we knocked down
HRI in CD34+ cells obtained from patients with sickle cell disease (SCD) (Fig. S12A).
This led to comparable increases in g-globin levels as in CD34+ cultures from healthy
donors shown above (Fig. S12B,C), and, as before, did not seem to affect erythroid
maturation (Fig. S12D). When grown under low oxygen tension cells expressing HRI
shRNAs were less prone to sickling than controls (Fig. 3F), suggesting that HRI depletion
might achieve therapeutically relevant levels of HbF.
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3.7 Mechanism of HbF elevation upon HRI depletion
BCL11A and LRF are the major direct repressors of g-globin transcription (56),
suggesting that the effects of HRI might converge on one or both of these factors as they
are expressed during overlapping time intervals of erythroid maturation (Fig. S13A,B). We
examined BCL11A and LRF protein levels by Western blot using extracts from CD34+
derived erythroblasts expressing HRI shRNAs. Notably, BCL11A but not LRF was
strongly depleted in both HRI knock-down samples (Fig. 4A) Western blots confirmed the
loss of HRI, the resulting reduction in phospho-eIF2α, and the increase in g-globin (Fig.
4A). GATA1 was unaffected, in agreement with ostensibly normal cell maturation under
conditions of HRI depletion.
We tested whether HRI controls BCL11A levels directly by governing its
translation, or indirectly, for example by controlling the translation of a nuclear factor that
promotes BCL11A transcription. Both BCL11A mRNA and primary transcript levels were
markedly reduced in HRI depleted cells, indicating that most if not all of the BCL11A loss
is a result of transcription inhibition in HRI-depleted primary erythroid cells, HUDEP2
pools and clonal lines (Fig. 4A and S14 A-D). To measure a possible contribution of direct
translational control of BCL11A mRNA by HRI we performed polysome profiling. HRI
depletion modestly increased overall translation efficiency as polysomal fractions were
slightly more abundant relative to monosomes (Fig. S15A). Moreover, in HRI depleted
cells BCL11A mRNA levels were significantly reduced across all polysomal fractions,
consistent with an overall loss in mRNA levels (Fig. S15B). To better visualize distribution
across fractions, results were plotted as percentage of total BCL11A mRNA, which
revealed little or no shift in the distribution pattern (Fig. S15C), suggesting that BCL11A
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mRNA translation plays only a minor if any role in response to HRI loss. α-globin mRNAs
tended to shift slightly to the larger polysome fractions (to the right), consistent with a
subtle increase in their translation (Fig. S15C).
To assess to what extent BCL11A loss accounts for the effects of HRI depletion,
BCL11A expression was restored in HRI-depleted HUDEP2 clonal cell lines. This
reinstated g-globin repression by 65% to 80% (Fig. 4B, Fig. S16A-D), suggesting that
BCL11A is a major HRI effector. Of note, depleting HRI in primary definitive (adult-type)
erythroid cells from murine fetal livers did not reduce BCL11A levels (Fig. S17 A-D),
suggesting that certain pathways controlled by HRI might be species specific. In sum,
BCL11A emerges as a HRI target in the control of HbF production in human adult
erythroid cells.
As a proof of principle, we assessed whether HRI’s effects on HbF can be amplified
with pharmacologic HbF inducers. Pomalidomide has been recently shown to induce HbF
in part by reducing BCL11A transcription (72). We tested the effects of pomalidomide
treatment on two HRI depleted HUDEP2 populations and control HUDEP2 cells. For
comparison we also included HUDEP2 cells in which BCL11A transcription was reduced
using a sgRNA targeting the erythroid BCL11A enhancer. These combinations did not
impair cell viability or maturation (Fig. S18A,D). All conditions alone elevated the fraction
of HbF+ cells and increased g-globin transcription as expected (Fig. 4C, Fig. S18B,C,E).
The strongest cooperativity was observed when HRI depletion was combined with
pomalidomide.
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3.8 Discussion
Using an improved CRISPR-Cas9 domain-based screening approach we identified
the erythroid specific kinase HRI as a potentially druggable target that is involved in HbF
silencing. Our findings contrast with previous reports showing that stabilization of eIF2αphosphorylation with the drug salubrinal can stimulate HbF synthesis in cultured human
erythroid cells (82, 83). Salubrinal acts downstream of HRI, and the mechanism underlying
the induction of HbF remains to be fully elucidated. Hematopoietic stress can be associated
with increased fetal hemoglobin levels. However, we believe that the effects of HRI
depletion are not due to stress, since there are seemingly little adverse effects on cell
viability and cell maturation as judged by cell morphological, surface phenotyping,
transcriptome, as well as proteome analysis. Moreover, silencing of HbF in HRI depleted
cells is largely restored upon BCL11A re-expression, consistent with a specific function of
HRI.
Mice in which the HRI gene has been knocked out appear largely normal, including
their hematological indices (84). This agrees with our results in human erythroid cell
cultures, and suggests that HRI loss is generally well tolerated. However, HRI mice
displayed impaired adaptation to erythropoietic stress induced by iron deficiency, and
exacerbated protoporphyria and thalassemia phenotypes (85, 86). It remains to be seen
whether HRI inhibition in SCD patients would elevate HbF levels sufficiently to improve
outcomes. HRI inhibition elevated HbF levels to a point at which it reduced cell sickling
in culture, suggesting that pharmacologic HRI inhibitors might provide clinical benefit in
SCD patients. Moreover, based on our results, combining HRI inhibition with an additional
pharmacologic HbF inducer might improve the therapeutic index.
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Fig. 1. A kinase-domain selective CRISPR-Cas9 screen identifies HRI as a novel fetal globin
repressor.
(A) Experimental outline. See Materials and Methods for full description. (B) Representative
HbF FACS gating strategy for sorting HbF high and HbF low populations for screens. (C)
sgRNA representation in HbF low vs. HbF high populations as log2 transformed normalized read
counts.
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Fig. 2. HRI depletion elevates g-globin in HUDEP2 cells. (A) Representative HbF FACS
for HUDEP2-Cas9 sgRNA pools. (B) Summary of HbF flow cytometry of cells expressing
indicated sgRNAs. Mean is shown ± standard deviation (SD) from (n=2) biological replicates.
(C) Western blots with antibodies against indicated proteins in cell pools expressing sgRNAs
listed at the top. (D) Mass spectrometry for HRI sgRNA #5 pool from (n=3) biological
replicates. log2 mean-normalized protein abundances in cells with HRI sgRNA #5 and nontargeting sgRNA, r-value denotes Pearson correlation coefficient. (E) RNA-seq of cell pools
with HRI sgRNA #5, log2 FPKM values averaged from (n=2) biological replicates.
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Fig. 3. HRI depletion elevates g-globin in primary erythroid CD34+ cells. (A)
Representative HbF flow cytometry on day 15 of CD34+ erythroid differentiation. (B)
Summary of HbF flow cytometry experiments. Error bars: SEM from 3 independent donors (*
denotes p-value<0.05, ** denotes p-value<0.01 from unpaired student T-tests). (C) g-globin
mRNA as fraction of g-globin + b-globin by RT-qPCR on day 13. Error bars: SEM from 3
independent donors (* denotes p-value<0.05, ** denotes p-value<0.01 from unpaired student
T-tests). (D) RNA-seq for CD34+ cells on day 13. R-value denotes Pearson correlation
coefficient. Data was obtained from one patient donor. (E) HPLC analysis of samples fomr cell
expressing annotated shRNAs, at day 15 of differentiation HbA: hemoglobin A (adult form);
HbF: fetal hemoglobin. Error bars: standard deviation from 2 independent donors. (F) Images
of sickle cell patient-derived erythroid cultures. Arrow heads mark cells with sickle-like
morphology. Bar graph: summary of blindly counted sickle shaped cells from 3 fields from one
patient with sickle cell disease.
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Fig. 4. HRI regulates BCL11A protein levels.
(A) Left: Western blot with indicated antibodies in cells uninfected, or infected with
virus expressing scrambled or HRI shRNAs on day 15 of differentiation. Right:
BCL11A mRNA (n=4 independent donors) and primary transcript (n=3 independent
donors) levels in HRI knock down cells as fraction of SC shRNA expressing cells.
Error bars are standard deviation from biological replicates. (B) BCL11A cDNA
rescue in HRI depleted HUDEP2 clonal cell lines. Data is RT-qPCR for g-globin as a
fraction of g-globin + β-globin. Error bars: standard deviation from two biological
replicates (C) HbF flow cytometry of indicated HUDEP2 sgRNA pools grown in the
presence or absence of pomalidomide. Error bar: SEM of 3 biological replicates.
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Fig. S1. sgRNA scaffold optimization. (See Supplementary Text for full description).
(A) Cas9 and sgRNA plasmid designs. (B) sgRNA scaffolds tested, modifications to
WT sgRNA-scaffold are highlighted in red. sgRNA 2.0 was previously described (26).
(C) sgRNA editing efficiency assessed in HCT116 cells. GFP+ populations were
measured at day 3 and day 16 post-sgRNA infection with sgRNAs targeting the essential
DNA replication gene RPA3, and the ROSA26 locus as a negative control. Fold
depletion was used to quantify editing efficiency for each of the sgRNA- scaffold
designs. (D) sgRNA editing efficiency was similarly assessed with sgRNA-scaffold
design 2.1 in HCT116, A-375, A549 and K562 cells lines. sgRNAs against the essential
DNA replication genes RPA3 and PCNA were used, as well as an sgRNA targeting the
ROSA26 locus as a negative control.
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Fig. S2. sgRNA 2.1 editing efficiency in HUDEP2 cells. (A) Experimental workflow
to verify editing efficiency in HUDEP2-Cas9 cells with the sgRNA 2.1 scaffold design.
After transducing sgRNAs, we harvested genomic DNA every 2 days over the course
of a total of 8 days. We amplified targeted regions by PCR, Sanger sequenced the
amplicons, and used TIDE to quantify editing efficiency. (B) Summary of targeting
efficiencies for time course. The proportion of edited CHD4 (48) alleles declined over
time, most likely because CHD4 is essential for cell growth or viability. (C)
Representative TIDE plot. Proportion of WT alleles remaining in population (0 bases
deleted or inserted) was taken to determine proportion of alleles that were edited. (D)
Representative HbF flow cytometry for BCL11A sgRNA control. (E) Representative
GFP flow cytometry at day 2 of screening protocol.
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Fig. S3. HRI’s role in regulating protein translation initiation. HRI is one of four
kinases known to phosphorylate the protein translation initiation factor eIF2α (28). In its
unphosphorylated form, eIF2α bound to GTP as part of a ternary complex with eIF2β and
eIF2γ recruits the first methionine tRNA to the 40S ribosomal subunit to form a preinitiation complex (PIC). The PIC then scans along the 5’UTR until it recognizes a start
codon, at which point the GTP bound to eIF2α is hydrolyzed to GDP and the eIF2 factors
are released from the PIC, allowing for formation of the 80S ribosomal unit. GDP is
released from the eIF2 complex by the guanine exchange factor eIF2B, which allows for
these factors to participate in further rounds of translational initiation. The phosphorylation
of eIF2α prevents its release from eIF2B, thus blocking the recycling of this factor and
further rounds of translation initiation. As such, the family of eIF2α kinases function as
general repressors of protein translation.
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Fig. S4. Tissue expression for HRI. (A) Tissue-wide expression profile for HRI from GTEx.
Expression levels for HRI are highest in whole blood. (B) Hematopoietic expression profile for HRI
from BloodSpot (http://servers.binf.ku.dk/bloodspot/) (97). Expression levels for HRI are highest
in the erythroid lineage. (C) Expression levels of eIF2α kinases in HUDEP2 cells and CD34+
erythroid cells. HRI is the highest expressed eIF2α kinase in these systems. It is worth noting that
while the other eIF2α kinases were included in the CRISPR-screen shown in Fig. 1, they were not
enriched in the HbF population, suggesting they are not expressed at high enough levels to impact
on HbF induction.
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Fig. S5. HRI domain architecture. Position of the six “hit” HRI sgRNAs within
the kinase domain.
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Fig. S6. Replicate concordance for mass spectrometry samples and normalization.
(A) Replicate experiments in differentiated HUDEP2 cells. (n=3) biological replicates
were generated each for HRI sgRNA #3, HRI sgRNA #5, and non-targeting sgRNA
HUDEP2-Cas9 cell pools. All 3 pairwise replicate comparisons are shown for each
condition. R-values denote Pearson correlation coefficients. Plots show log2 protein
abundance for each replicate displayed. (B) Replicate experiments in undifferentiated
HUDEP2 cells. (n=3) biological replicates were generated each for HRI sgRNA #3, HRI
sgRNA #5, and non-targeting sgRNA HUDEP2-Cas9 pools. All 3 pairwise replicate
comparisons are shown for each sample. R-values denote Pearson correlation coefficients.
Plots show log2 protein abundance for each replicate displayed. (C) Normalization for mass
spectrometry data. Protein abundances were log2 transformed (left panel), and normalized
to their mean (right panel).
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Fig. S7. Mass spectrometry analysis for HUDEP2Cas9 HRI sgRNA pools. (A) Volcano plot for
differentiated HRI sgRNA #5 vs. non-targeting
sgRNA HUDEP2-Cas9 pools. (B) Scatter plot and
volcano plot for differentiated HRI sgRNA #3 vs.
non-targeting sgRNA HUDEP2-Cas9 pools. (C)
Scatter plot and volcano plot for undifferentiated HRI
sgRNA #5 vs. non-targeting sgRNA HUDEP2-Cas9
pools. (D) Scatter plot and volcano plot for
undifferentiated HRI sgRNA #3 vs. non-targeting
sgRNA HUDEP2-Cas9 pools. In all panels, data
represent mean protein abundances from 3 biological
replicates. P-values were determined from student Ttests.
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Fig. S8. RNA-seq for HUDEP2 cells. (A) MA plots for HRI sgRNA #5 and nontargeting sgRNA HUDEP2-Cas9 pools. 2 RNA seq biological replicates were
generated each for differentiated cells. R-values denote Pearson correlation
coefficients across the two indicated replicates. (B) Volcano plot for differentiated
HRI sgRNA #5 and non-targeting sgRNA pools. Statistical significance was
determined using the R-package DESeq2, with a negative binomial as a null
distribution to determine statistical significance. P-values were FDR corrected for
multiple hypothesis testing. Vertical lines denote 2 fold changes, and the horizontal
line denotes a significance level of 10-20.
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Fig. S9. RT-qPCR for six
“hit”
HRI
depleted
HUDEP2 pools. Cells
were differentiated for 7
days for all data shown in
this figure. (A) mRNA
levels of indicated genes.
(B) Primary transcript
levels of indicated genes.
(C) mRNA levels of αglobin, ALAS2, BAND3
and GATA1. In all panels
error
bars
represent
Standard deviation; n=2
biological replicates.

73

Fig. S10. HRI depleted HUDEP2 clones. Given the heterogeneity of mutations induced
by sgRNAs in pools (see Fig. S2), we generated clonal HUDEP2 HRI depleted cell lines
from the HRI sgRNA#5 pool. Cells were differentiated for 7 days for all data shown in
this figure. In all panels error bars represent SEM; n=3 biological replicates. (A) AntiHRI Western blot from lysates of two clonal HRI depleted cell lines and control cells.
(B) HbF flow cytometry for HRI depleted clonal cell lines (gates were set on negative
control as in Fig 2A). (C) RT-qPCR for globins for HRI depleted clonal cell lines, mean
is shown ± standard error of the mean (SEM) from (n=3) biological replicates. (D)
Primary transcripts of β-type globins. (E) mRNA levels of indicated genes.
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Fig. S11. Cell surface markers and cell morphology for HRI depleted CD34+ cells.
(A) Representative transduction levels for shRNAs by GFP flow cytometry (Day 11).
Uninfected were used as a gating control (blue) and compared to shRNA transduced
populations (red). The uninfected control is the same for all panels shown. (B)
Representative CD71/CD235a staining for SC shRNA and HRI shRNAs infected
CD34+ cells at day 15 of culture. (C) Giemsa staining for SC shRNA control and HRI
shRNAs infected CD34+ cells at day 15 of culture. 2 fields of view are shown for each
sample.
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Fig. S12. RTqPCR for HRI
depleted
sickle
CD34+
cells.
Results are from
one patient with
SCD on day 13 of
differentiation. (A)
HRI mRNA levels.
(B) g-globin mRNA
as fraction of g- + βglobin. (C) mRNA
levels of indicated
genes. (D) mRNA
levels of indicated
genes.
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Fig. S13. HRI and BCL11A expression during erythroid maturation. (A) RT-qPCR for
indicated primer sets for (n=2) technical replicates from one patient donor. Maturation
markers a-globin, ALAS2 and BAND3 increase during erythroid maturation. HRI
progressively increases during maturations. BCL11A increases early in maturation and then
declines. (B) Western Blot for HRI, BCL11A and LRF during erythroid maturation. HRI
increases in protein levels during maturation. BCL11A protein levels increase and then
progressively decrease as shown previously (98). LRF remains relatively unchanged during
maturation, as shown previously (56). These results suggest that BCL11A expression partly
precedes HRI expression. The anti-correlated expression levels of HRI and BCL11A might
appear in conflict with a requirement of HRI for BCL11A expression. However, please note
that while HRI levels increase during erythroid maturation, its activity seems to decline as
shown by western blots measuring eIF2⍺-P levels (Fig.2C), most likely due to the production
of heme as a result of erythroid differentiation (26).
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Fig. S14. BCL11A Western blots and RT-qPCR in
HRI depleted HUDEP2 cells. (A) BCL11A Western
Blot for HUDEP2 HRI sgRNA pools (from Fig. 2). (B)
BCL11A Western blot in HUDEP2 HRI depleted clones
(from Fig. S10). (C) BCL11A total and primary
transcript levels for HRI sgRNA pools and HRI depleted
clonal HUDEP2 cells. Transcript levels were
normalized to LRF and fold changes are shown here
relative to non-targeting sgRNA HUDEP2 cells which
served as a negative control. (D) BCL11A transcript
levels in RNA-seq from Fig. 3F.
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Fig. S15. Polysome profiling in primary erythroid cells. (A) Polysome tracings for
shRNA transduced CD34+ erythroid cultures (Day 13). (B) Transcript abundances for each
polysomal fraction normalized to spike-in control. (C) Transcript distribution across
polysomal fractions. The proportion of transcripts for each fraction was determined by
dividing the transcript abundance by the total amount of transcript across all the fractions
(shown here as % of total). Polysome profiling was performed from cultures derived from
(n=2) independent patient donors. Error bars are standard deviations for (n=2) technical
replicates.
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Fig. S16. Gene expression measurements in the BCL11A rescue experiments.
Presence or absence of BCL11A cDNA is indicated by + or -, respectively. Cells were
differentiated for 7 days for all data shown. Error bars: standard deviation from 2
biological replicates. (A) BCL11A transcript levels. While BCL11A transcripts were
slightly higher in cells lines expressing exogenous BCL11A cDNA, they remained in a
similar range to endogenous levels. (B) mRNA levels of indicated genes. BCL11A
expression strongly reduced g- and e-globin transcript levels. (C) Primary-transcript
levels of indicated genes. BCL11A expression strongly reduced g-globin primary
transcript levels. (D) Transcript levels for maturation markers. We note that expression
BCL11A cDNA slightly reduced alpha-globin and BAND3 levels, but were not
significantly different to levels from parental HUDEP2 cells.
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Fig. S17. HRI depletion in fetal liver derived adult-type erythroblasts. (A)
Experimental approach, for details see Methods and Materials. (B) Western Blot for HRI,
BCL11A and β-actin for all denoted conditions. HRI depletion did not result in reduced
BCL11A protein levels. (C) Image J quantification of protein levels from (n=2)
independent biological replicates. Error bars denote standard deviations. (D) RT-qPCR
for denoted transcripts. Data were collected from (n=2) biological replicates, error bars
represent standard deviations. HRI depletion did not affect BCL11A or embryonic-type
globin transcript levels, or maturation as evidenced by ⍺-globin levels.
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Fig. S18. Gene expression measurements in the pomalidomide combination
experiments. Cells were differentiated for 7 days for all data shown with sgRNA
HUDEP2-Cas9 pools. N denotes Non-targeting sgRNA, B denotes BCL11A sgRNA,
3 denotes HRI sgRNA #3, and 5 denotes HRI sgRNA#5. (A) Cell viability assessed by
flow cytometry. (B) g-globin mRNA as fraction of g- + β-globin. (C) Globin profiles
(mature transcripts) (D) mRNA levels of indicated genes. Error bars: standard
deviation from 2 biological replicates. (E) Primary-transcript levels of indicated genes.
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Table 2

Table S1. Top differentially expressed proteins from HUDEP2 mass spectrometry.
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Table 1

Table S2. Top differentially expressed transcripts from HUDEP2 RNA-seq.
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Name
BCL11A_Exon2_#1_F
BCL11A_Exon2_#1_R
BCL11A_Exon2_#2_F
BCL11A_Exon2_#2_R
BCL11A_+58_F
BCL11A_+58_R
CHD4_Exon16_F
CHD4_Exon16_R
CHD4_Exon17_F
CHD4_Exon17_R
CHD4_Exon22_F
CHD4_Exon22_R
EIF2AK1_sgRNA#1_F
EIF2AK1_sgRNA#1_R
EIF2AK1_sgRNA#2_F
EIF2AK1_sgRNA#2_R
EIF2AK1_sgRNA#3_F
EIF2AK1_sgRNA#3_R
EIF2AK1_sgRNA#4_F
EIF2AK1_sgRNA#4_R
EIF2AK1_sgRNA#5_F
EIF2AK1_sgRNA#5_R
EIF2AK1_sgRNA#6_F
EIF2AK1_sgRNA#6_R
Non_targeting_sgRNA_F
Non_targeting_sgRNA_R

Sequence
CACCGTGAACCAGACCACGGCCCGT
AAACACGGGCCGTGGTCTGGTTCAC
CACCGCATCCAATCCCGTGGAGGT
AAACACCTCCACGGGATTGGATGC
CACCGTTGCTTTTATCACAGGCTCC
AAACGGAGCCTGTGATAAAAGCAAC
CACCGAACTCATTCTCTCGGATGA
AAACTCATCCGAGAGAATGAGTTC
CACCGCTGATTGTTCTTCAGCCGAT
AAACATCGGCTGAAGAACAATCAGC
CACCGAAATACGAACGCATCGATGG
AAACCCATCGATGCGTTCGTATTTC
CACCGTCTGGAAGTGCTCTCCGACC
AAACGGTCGGAGAGCACTTCCAGAC
CACCGTATCCACCTTTTCCTAAGA
AAACTCTTAGGAAAAGGTGGATAC
CACCGTTTTAGTTGCACCCTTAATC
AAACGATTAAGGGTGCAACTAAAAC
CACCGTTGTTGGCTATCACACCGCG
AAACCGCGGTGTGATAGCCAACAAC
CACCGATAGTCGAGAGAAACAAGCG
AAACCGCTTGTTTCTCTCGACTATC
CACCGTGGTGAACTTGAGTCGACCC
AAACGGGTCGACTCAAGTTCACCAC
CACCGACCGGAACGATCTCGCGTA
AAACTACGCGAGATCGTTCCGGTC

Table S3. Oligos for sgRNAs.
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Name
BCL11A_Exon2_#1_TIDE_F
BCL11A_Exon2_#1_TIDE_R
BCL11A_Exon2_#2_TIDE_F
BCL11A_Exon2_#2_TIDE_R
BCL11A_+58_TIDE_F
BCL11A_+58_TIDE_R
CHD4_Exon16_TIDE_F
CHD4_Exon16_TIDE_R
CHD4_Exon17_TIDE_F
CHD4_Exon17_TIDE_R
CHD4_Exon22_TIDE_F
CHD4_Exon22_TIDE_R

Sequence
ATGCAAACAGCTTTTCTCCTTGC
CACATTTGTTGCTGTGGGTGTG
CCAGAGAGAAGGTGTCTGATGTGT
AGATGTGCTTCTCCCCTTTCTGTC
GTAGCTGGTACCTGATAGGTGCC
GGAAAACAGCCTGACTGTGCC
GAGCCCAAAATAGCCATGTCAATG
TGTAGTTATGGTGGGACCTTGGG
GTGCTGGAGTGAGTAACCATTCAAT
CGCATGAAGGTATCTCAGGGGA
GCTATTTGAGCTTGAACAAGTCCTGAC
TGTTCTCAGGAAGCTCCTAAGATGC

Table S4. Primers used for TIDE assays shown in Fig. S2.
Name
HRI_shRNA1_F
HRI_shRNA1_R
HRI_shRNA4_F
HRI_shRNA4_R
LRF_shRNA_F
LRF_shRNA_R
SC_shRNA_F
SC_shRNA_R
Luciferase_shRNA
_F
Luciferase_shRNA
_R
TurboGFP_shRNA
_F
TurboGFP_shRNA
_R
mHRI_shRNA_1_
F
mHRI_shRNA_1_
R
mHRI_shRNA_2_
F
mHRI_shRNA_2_
R

Sequence
CACCGGCAGAGAGCAATGTGGTGTTAACTCGAGTTAACACCACATTGCTCTCT
GTTTTTG
AATTCAAAAACAGAGAGCAATGTGGTGTTAACTCGAGTTAACACCACATTGCT
CTCTGCC
CACCGGGCAGAAGTTCTAACAGGTTTACTCGAGTAAACCTGTTAGAACTTCTG
CTTTTTG
AATTCAAAAAGCAGAAGTTCTAACAGGTTTACTCGAGTAAACCTGTTAGAACTT
CTGCCC
CACCGGCCACTGAGACACAAACCTATTCTCGAGAATAGGTTTGTGTCTCAGTG
GTTTTTG
AATTCAAAAACCACTGAGACACAAACCTATTCTCGAGAATAGGTTTGTGTCTCA
GTGGCC
CACCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTT
GTTTTTG
AATTCAAAAACAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCT
TGTTGCC
CACCGGCGCTGAGTACTTCGAAATGTCCTCGAGGACATTTCGAAGTACTCAG
CGTTTTTG
AATTCAAAAACGCTGAGTACTTCGAAATGTCCTCGAGGACATTTCGAAGTACT
CAGCGCC
CACCGGCGTGATCTTCACCGACAAGATCTCGAGATCTTGTCGGTGAAGATCA
CGTTTTTG
AATTCAAAAACGTGATCTTCACCGACAAGATCTCGAGATCTTGTCGGTGAAGA
TCACGCC
CACCGGTGGTGTTAAAGATAATGAAAGCTCGAGCTTTCATTATCTTTAACACC
ATTTTTG
AATTCAAAAATGGTGTTAAAGATAATGAAAGCTCGAGCTTTCATTATCTTTAAC
ACCACC
CACCGGCAGCCATTCGGGACAGAAATGCTCGAGCATTTCTGTCCCGAATGGC
TGTTTTTG
AATTCAAAAACAGCCATTCGGGACAGAAATGCTCGAGCATTTCTGTCCCGAAT
GGCTGCC

Table S5. shRNA oligos.
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Name

Sequence

LRG_
F2
LRG_
R2
PE-5

TCTTGTGGAAAGGACGAAACACCG

PE-7

TCTACTATTCTTTCCCCTGCACTGT
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCT
CTTCCGATCT
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACC
GCTCTTCCGATCT

Table S6. sgRNA sequencing library primers.
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Name

Sequence

Gamma_globin_F

TGGCAAGAAGGTGCTGACTTC

Gamma_globin_R
Beta_globin_F
Beta_globin_R
Alpha_globin_F
Alpha_globin_R
Gamma_globin_PT_F
Gamma_globin_PT_R
Beta_globin_PT_F
Beta_globin_PT_R
ALAS2_F
ALAS2_R
BAND3_F
BAND3_R
GATA1_F
GATA1_R
HRI_F
HRI_R
BCL11A_F
BCL11A_R
ZBTB7A_F
ZBTB7A_R
Mouse_HRI_F
Mouse_HRI_R
Mouse_Bcl11a_F
Mouse_Bcl11a_R
Mouse_ey-globin_F
Mouse_ey-globin_R
Mouse_bh1-globin_F
Mouse_bh1-globin_R
Bactin_F
Bactin_R

GCAAAGGTGCCCTTGAGATC
TGGGCAACCCTAAGGTGAAG
GTGAGCCAGGCCATCACTAAA
AAGACCTACTTCCCGCACTTC
GTTGGGCATGTCGTCCAC
TTTGTGGCACCTTCTGACTG
GCCAAAGCTGTCAAAGAA
GCTAGGCCCTTTTGCTAATC
CTGGTGGGGTGAATTCTT
CAGCGCAATGTCAAGCAC
TAGATGCCATGCTTGGAGAG
ACCTCTCTCACCTCACCTTCTG
AACCTGTCTAGCAGTTGGTTGG
CTGTCCCCAATAGTGCTTATGG
GAATAGGCTGCTGAATTGAGGG
CACCCGAACAGTTGGAAGGA
AGAGCTCTAGCAGGACCACA
ACAAACGGAAACAATGCAATGG
TTTCATCTCGATTGGTGAAGGG
GCTTGGGCCGGTTGAATGTA
GGCTGTGAAGTTACCGTCGG
CTGCTGCAGAGTGAGCTTTTTC
CTGAGAAAGGAGGCTTAGTTGC
GCCCCAAACAGGAACACATA
GGGGCATATTCTGCACTCAT
ACAGCTTTGGGAACTTGTCCTC
TCTCCAAAAGCAGTCAGCACC
AGGCAGCTATCACAAGCATCTG
AACTTGTCAAAGAATCTCTGAGTCCA
ACACCCGCCACCAGTTC
TACAGCCCGGGGAGCAT

Table S7. RT-qPCR primers.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
4.1 Conclusions
In these studies, we have used a domain-focused CRISPR-Cas9 screen with which
we have identified the kinase HRI as a regulator of fetal hemoglobin. We have shown that
depleting this kinase induces HbF in a specific fashion without affecting cell maturation in
both HUDEP2 cells and primary erythroid cultures. The effects appear to be mediated in
part through a transcriptional downregulation of BCL11A. Finally, depleting the effects of
depleting this kinase are amplified in combination with the HbF inducer pomalidomide.
These studies thus suggest that HRI may be used as a drug target for hemoglobinopathies,
and show that these types of genetic screens may further uncover regulators of fetal
hemoglobin that could serve as therapeutic targets for these disorders.
By their nature, these types of screens do not guarantee that HbF regulators will be
identified. But it is perhaps not entirely surprising that they have been able to uncover
regulators that had not been previously characterized. In light of Johnathan Pritchard’s
omnigenic model of gene regulation (87), in that almost all expressed genes in a cell can
virtually affect any trait given how interconnected regulatory networks are, there may be a
number of genes that play a role in regulating fetal hemoglobin, and many have already
been characterized (48). But perhaps the more surprising finding of our studies is the
specificity of the induction of HbF. The specific mechanistic reasons for this are still
unclear, but it is certainly possible that the screen selects for such hits. Once the sgRNA
libraries are transduced, the cells are expanded for 8 days and differentiated for 7 days. The
depletions have to be relatively well tolerated for the duration of the screens for any hits to
eventually be identified. The screens thus probably select for targets that can target HbF in
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a relatively specific fashion. We have now also seen this with other targets we have
identified with other screening libraries.
Our current model is that HRI may play a role in regulating BCL11A transcription,
which in turn controls HbF levels (Figure 4.1). Given HRI’s role as a regulator of
translation, we hypothesize that HRI might control one or several transcription factors that
transcriptionally regulate BCL11A expression. eIF2⍺ kinases are known to translationally
regulate several transcription factors including ATF4 and DDIT3 (88). The transcripts for
these transcription factors have one or multiple short upstream open reading frames
(uORF) in their 5’UTRs. These elements can be quite common in some contexts as
identified by genome-wide based on ribosome footprinting assays. Approximately 25% of
transcripts in murine embryonic stem cells have been shown to have uORFs with actively
engaged ribosomes (89). Some studies have suggested that up to 50% of transcripts might
have such uORFs (88, 90), but it remains to be seen to what extent this may reflect technical
differences in the analysis of translation efficiencies (88). Non-cognate start codons,
particularly CUG, are typically found to be most common found in these elements (89, 94).
One recent study showed that, in murine erythroid cells, approximately 10% of transcripts
had uORFs with associating ribosomes (23), suggesting that the extent to which such
elements can be found in 5’UTRs may also be context specific. It is also important to note
that while a broad range of been identified, only a handful of these have been functionally
characterized. Generally, uORFs are thought to reduce translation of the downstream
reading frame (88). This is either due to ribosome dissociation at the stop-codon of the
uORF, or the translated uORF peptide can function as an attenuator of translational
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elongation and lead to ribosome stalling within the uORF, thus blocking further preinitiation complexes from progressing.
The phosphorylation of eIF2⍺ inhibits its recycling after one round of translation
as detailed above and reduces the available amount of this factor for further protein
synthesis. This generally disfavors translation of uORFs, as is the case for the GADD34
which codes for a subunit of protein phosphatase-1 which dephosphorylates eIF2⍺ (88).
The GADD34 transcript has one such uORF and when eIF2⍺ is phosphorylated, the
translation of its downstream coding messenger ORF is diminished. It has been proposed
that, when available eIF2⍺ levels are low due to its phosphorylation, the pre-initiation
complexes may begin scanning through the 5’UTR without associating with eIF2 factors,
and only bind eIF2⍺ further downstream in the 5’UTR once past the uORF (88).
Alternatively, it is possible phosphorylated eIF2⍺ can associate with pre-initiation
complexes but alter the efficiency of recognition of start codons to reduce initiation at the
uORF, though this seems to be less likely (88). Regardless of the proposed model, the end
result is that phosphorylation of eIF2⍺ favors translation of the downstream GADD34
messenger ORF. Once the GADD34 protein is synthesized, it then de-phosphorylates
eIF2⍺, thus providing an auto-regulatory mechanism for eIF2⍺-phosphorylation. These
mechanisms of translation can become much more complex when multiple uORFs are
present within a 5’UTR, as some uORFs do allow for translation re-initiation. This is the
case for ATF4, which is normally lowly translated, but when eIF2⍺-phosphorylation is
high, the delayed re-initiation of ribosomes re-initiating downstream of its first uORF
diverts them from a second inhibitory uORF, which then allows for translation of its
messenger ORF (88). It is thus possible that HRI controls other transcription factors
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translationally through one or multiple of these mechanisms, which may in turn control
BCL11A expression.

4.2 Characterizing mechanism of HRI’s regulation of HbF
A number of follow-up studies are now of interest to further characterize
mechanistically how HRI controls HbF levels, test the specific domains of HRI that are
required for this role and further dissecting its regulatory pathway, and investigate drug
combinations with HRI depletion that may indicate further therapeutic strategies.

4.2.1 Transcription factor CRISPR screen
Towards an initial attempt to better understand how HRI controls fetal hemoglobin
levels mechanistically, one approach we have thought of is to characterize more broadly
which transcription factors are involved in regulating fetal hemoglobin. As overviewed in
the introduction, a number of transcriptional regulators have been implicated in regulating
HbF, with the major repressors being the DNA binding proteins BCL11A and LRF, but it
is still unclear which other factors may play a role in this process. Furthermore, as the
BCL11A enhancer is being more extensively characterized, it will be of interest to know
which set of factors are required for the transcriptional regulation of this factor. Towards
this goal, we’ve made use of another sgRNA library developed by Junwei Shi which targets
essentially all annotated DNA binding domains of the human genome (91). This library is
well distributed across all these domains, and includes approximately 9,000 sgRNAs with
1,400 different transcription factors targeted. We have now tested this library in the
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HUDEP2 cultures as we had done the kinase-domain screen. These screens revealed
several factors that may function as fetal hemoglobin repressors (Figures 4.2 and 4.3). One
of these is the transcription factor NFIA which is part of a family of 4 transcription factors
that play diverse roles in regulating transcription during development and in multiple
tissues (92). HPFH variants have previously been shown to map to one of these family
members, NFIX. Initial validation experiments suggest that both NFIA and NFIX regulate
HbF, and the mechanism may involve BCL11A or Lin28B (data not shown, generated by
Peng Huang, postdoc in our lab) but whether these are direct or secondary effects still
remains to be determined. These factors do not seem to be perturbed upon HRI depletion,
so they may not be its direct effectors. Another factor that was identified from this screen
is WT1. This transcription factor has been studied in the context of Wilms tumor, which is
a pediatric renal malignancy (93). We are still validating this factor, and its connection to
HRI is to be determined. A number of other factors were identified in the screen as well
that appeared to have a more intermediate phenotype. Initial validation experiments for
REST showed a robust HbF induction (data not shown and generated by Xianjiang Lan, a
postdoc in our lab), suggesting it may be worthwhile validating other factors which scored
in this intermediate range as well. Some of these may be related to HRI’s effects on HbF,
but may also be worth pursuing in their own right as well.

4.2.2 Ribosome profiling
As stated above, we are currently hypothesizing that HRI controls one or several
transcription factors translationally. Differential eIF2⍺-phosphorylation levels are known
to influence the translation of a number of transcripts, including those for several
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transcription factors. A recent study in murine erythroid cultures showed that a number of
factors have translated uORFs in their 5’UTRs (23), including BCL11A, and may be
translationally regulated, but this has yet to be characterized in human systems.
Furthermore, the extent to which differential eIF⍺-phosphorylation levels regulate
translation through uORFs globally is still an open question. Ribosome profiling is
perfectly suited to study these questions, as it allows to map ribosome occupancy on
transcripts with single nucleotide resolution in a genome-wide fashion (94). This method
is similar to polysome profiling that was presented above. The first step of the method is
to arrest translation by treating cells with cycloheximide. Cells are then lysed and
ribosomes isolated using a sucrose cushion. Ribosome footprints are generated by nuclease
digestion. Fragments protected by ribosomes (typically 28 to 30 nt in length) are not
digested, these can be recovered for deep sequencing. The drug harringtonine blocks
protein synthesis and leads to the accumulation of ribosomes at translation initiation (89,
94). This can be useful to precisely map sites of translation initiation. This method can be
adapted to different cell types and different conditions, and thus may be particularly useful
in characterizing HRI’s downstream targets that may be involved in regulating fetal
hemoglobin.

4.3 Domain analysis of HRI
Another set of follow-up experiments that could provide insight into HRI’s role in
regulating fetal hemoglobin is to further dissect which of its domains and activities are
required for this function. Given that our sgRNAs and shRNAs lead to a near complete loss
of the total protein, it is still unclear if the effects on HbF are due to a reduction in the total
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level of the protein, or is specifically due to its enzymatic activity. To test this, we have
tried doing rescue experiments by adding back HRI cDNA to cells in which it has been
depleted. The cDNA can then be mutated to abrogate its kinase activity to directly test if
this enzymatic function is required for the effects on HbF. We have tried multiple
approaches to do these experiments, but HRI has been challenging to overexpress. We are
now trying to do this with virus-free approaches, but it still remains to be seen how these
will work.
Another approach to characterize HRI’s role in regulating HbF is to perform a tiling
screen along the coding sequence for this kinase. We have designed such a library which
covers it quite well (Figure 4.4). This approach might help pinpoint specific domains within
HRI that may be specifically required for HbF regulation. This is limited though by the fact
that many sgRNAs lead to a strong depletion of the kinase, and resolving whether effects
are due to a specific loss of function of a given domain versus degradation of the protein
would be challenging. It might be possible to knock-in GFP into the endogenous HRI gene
and then select for cells that have not lost HRI total expression at the end of the screen.
Lastly, while we are currently hypothesizing that HRI mediates its effects on HbF
through its role on regulating protein translation, other eIF2⍺ kinases are known to have
other targets than eIF2⍺. To assess to what extent the effects on HbF are mediated through
this factor, we could knock-in a S51A mutant into this gene to abrogate its ability to be
phosphorylated. This mutant has been characterized in murine models recently (95), and
could be useful in this context to further dissect whether this canonical pathway is involved
in HbF regulation. If this showed that a target other than eIF2⍺ is implicated, then
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phosphor-proteomics may allow to elucidate other targets than may be involved in this
process.

4.4 Combination therapy experiments
As shown above, while depleting HRI leads to an increase in HbF levels, its effects
are partial, and certainly do not reach the same level of induction as BCL11A or LRF. It is
thus unclear whether targeting HRI would lead to a strong enough elevation of HbF to be
clinically useful. We showed that combining HRI depletion with the HbF inducing drug
pomalidomide amplifies the effects on HbF. This suggests that if an inhibitor could be
developed to block HRI, or lead to its depletion using a thalidomide derivative for chemical
degradation, this approach could be combined with other HbF inducing drugs to lead to a
robust induction while hopefully using lower drug dosages to limit off-target effects. It is
worth pointing out that combination therapy may be the most adapted approach for the
treatment of hemoglobinopathies. The few factors that were identified from the GWAS
studies may be the only targets that be adapted for treatment with a single agent target, as
these factors’ reduction in patients are relatively well tolerated, and small perturbations
such as SNPs are enough to give a significant induction of HbF. BCL11A in particular is
a potent repressor, and if it could be targeted with a compound using a chemical
degradation system previously described (96), it could certainly serve as a very useful
pharmacologic target if this can be accomplished in a tissue specific fashion. Combination
therapy has its own set of challenges, but does offer the possibility to minimize off-target
effects of each drug will maximizing on-target activity.
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To this end, we are currently further investigating combination treatments with
other known HbF inducing drugs including hydroxyurea (HU) and the recently described
G9a inhibitor (UNC0638) presented in the introduction (work done by Scott Peslak,
clinical fellow in the lab). So far, HU has little additive effect with HRI depletion in primary
erythroid cultures, but both pomalidomide and the G9a inhibitor have additive if not
synergistic effects on HbF levels. It still remains to be seen to what extent these effects are
specific, but the combination of these treatments seems to be well tolerated by the cells and
do not affect erythroid maturation.
Another approach to characterize factors that may have additive or synergistic
effects with HRI would be to repeat similar CRISPR screens as outlined above, but either
in the context of HRI depletion, or not. If sgRNAs show differential enrichment across
these different conditions, this may be indicative of such a combinatorial effect. These
types of approaches can be easily adapted to testing combination treatments over the
background of a single depletion such as HRI. This only involves transducing these
libraries in the depleted cell lines. Perhaps the more challenging aspect of these types of
screens is the number of possible libraries to screen for, and which of these to use. It would
be possible to do a genome-wide screen on the background of an HRI depletion, which
may be better adapted for this particular goal. The quality of the screen would depend on
how well such libraries deplete their targeted factors, particularly as many of these use
early exon targeting sgRNAs as opposed to being domain-targeted. A few approaches also
allow multiplexing sgRNAs in the same expression vector. Such approaches allow for
essentially all inner combinations of a given library, which can in theory cover more
permutations of sgRNAs, but also lead to very large library sizes.
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Figure 4.1 – Model for HRI‘s control of fetal hemoglobin expression. We
hypothesize that HRI translationally controls one or a set of transcription
factors that in turn regulate BCL11A expression which then influences fetal
globin levels.
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Figure 4.2 – Transcription factor CRISPR screen. Several TFs were identified as
being potential fetal hemoglobin repressors including NFIA and WT1. Control
sgRNAs are also indicated.
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Figure 4.3 – Transcription factor CRISPR screen. This is the same data as in
Figure 4.2 but the median read counts for each gene are shown to simplify the
display. A number of TFs scored in a more intermediate range in this screen.

100

Figure 4.4 – Tiling screen sgRNA distribution along HRI open reading frame. This
library contains approximately 300 sgRNAs with over 50% of them being less than
5bp appart, and over 90% being 20bp apart.
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